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ABSTRACT OF THE DISSERTATION 
 
Identification of novel protein targets of metronidazole in drug sensitive and resistant strains of 
Trichomonas vaginalis and examination of the role of Mycoplasma hominis in secretion of 
cytokines released from primary human monocytes 
 
by 
 
Fitz Gerald Iheanyichukwu Diala 
Doctor of Philosophy in Molecular Biology 
University of California, Los Angeles, 2020 
Professor Patricia J. Johnson, Chair 
 
Trichomonas vaginalis, an extracellular, flagellated protozoan parasite, is the etiologic 
agent for trichomoniasis, the most common non-viral sexually transmitted infection, 
trichomoniasis. While asymptomatic presentation is commonplace, symptomatic infections 
typically present as vaginitis and cervicitis in women, and urethritis in men. Only 5-
nitroimidazole class of drugs, metronidazole (Mz) and tinidazole, is FDA-approved for treatment 
of infections. To overcome the knowledge gap in Mz targets in T. vaginalis, we used 
metronidazole-alkyne analog and we employed copper(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) “click” reaction to enrich these protein targets. Using tandem mass tag quantitative 
proteomics, we identified novel protein targets in Mz-sensitive and -resistant parasites. We also 
determined through activity-based protein profiling that metronidazole binds to cysteine residues 
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and subsequently identified cysteine residues that are bound by metronidazole. As the nature of 
immune response to T. vaginalis infection appears to vary, we also explored whether T. vaginalis 
parasites harboring M. hominis, an endosymbiont, induce the production of different cytokines 
from primary human monocytes compared to parasites that do not harbor the endosymbiont. 
Indeed, we observe that more cytokines are elaborated in response to M. hominis infected 
parasites. Together, these studies illuminate our knowledge of this important human pathogen, 
pharmacologically and immunologically. 
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Chapter 1 : General Introduction 
 
  
2 
 
Trichomonas vaginalis is a microaerophilic protozoan parasite that is the causative agent 
of trichomoniasis, a sexually transmitted infection afflicting men and women1. The estimated 
prevalence of trichomoniasis is over 250 million worldwide1, with about 3.7 million cases in the 
United States2, making trichomoniasis the most prevalent non-viral STI in the world and the US1. 
As an extracellular parasite, T. vaginalis has to adhere and lyse host cells3 to obtain nutrient4 and 
establish infection.  
Importantly, the bulk of infections are asymptomatic; however, symptomatic presentation 
result from pain and inflammation of affected urogenital organs1. In women, symptoms include 
vaginitis, cervicitis, and vaginal discharge1, with complications including pelvic inflammatory 
disease5 and Fitz-Hugh-Curtis syndrome6, as well as premature rupture of membranes, premature 
delivery, and low birth weight babies in pregnant women7. In men, urethritis1 and prostatitis2 are 
notable symptoms. Trichomoniasis is also associated with increased risk of HIV infection and 
transmission1, presumably because of increased traffic of immune cells into the urogenital tract 
of infected patients8,9. 
 
Trichomoniasis treatment and mechanism 
The absence of symptoms in infected individuals might lead them to not seek treatment10, 
thus leading to increased spread of infection. Given the potential for harm to infected patients, it 
is important to have robust treatment regimens for trichomoniasis. Trichomoniasis is responsive 
to treatment with 5-nitroimidazole drugs, with metronidazole and tinidazole the only FDA-
approve ones11. Both metronidazole and tinidazole are prodrugs that differ only in their side 
chains. Unfortunately, resistance to metronidazole has been reported ranging from 4.3% of 
isolates in the US11 to 17.4% in the Goroka region of Papua New Guinea12.  
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Metronidazole diffuses passively into the parasite13, and is activated by redox enzymatic 
processes in the hydrogenosome14,15, a mitochondria-related organelle16, and in the cytoplasm17. 
Activated drug then binds to macromolecules18. In vitro evidence exists that the drug is able to 
bind to proteins in susceptible anaerobic and microaerophilic parasites T. vaginalis17, Entamoeba 
histolytica19, and Giardia duodenalis20, and to DNA18.  
While the activated metronidazole is a promiscuous nitroradical anion21, previous work 
had only demonstrated the identification of very few proteins17,19,20 and suggested specific 
limited number of targets17. It is likely that metronidazole activation in the hydrogenosome and 
cytoplasm results in adduction to more proteins than previously reported.  
 
Immune cells’ response to Trichomonas vaginalis  
Effective immune response to trichomoniasis is very important, especially given the 
possible documented complications with this infection. Given that partner reinfection is 
common1, thus necessitating the empiric treatment of the patient’s sexual partners, it highlights 
the fact that adaptive immune response formed following infection might not be fully protective. 
Lysis of the epithelial layer allows for possible interaction between T. vaginalis and cells of the 
immune system, which traffic to the site of injury22. T. vaginalis is a phagocytic organism that is 
able to phagocytose different cells, including bacteria and human cells, including leukocytes4,23. 
Vaginal discharge is one symptom of T. vaginalis infection, and has been demonstrated to 
contain neutrophils8. T. vaginalis isolates can exhibit a range of differences, including adherence 
and cytotoxicity3, which are necessary for infection. The impact of varied virulence of T. 
vaginalis strains on the quality of immune response mounted in response to infection deserves 
exploration. In addition to virulence differences secondary to expression of different proteins in 
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different strains24, differences have also been attributed to the presence of an endosymbiont, 
Mycoplasma hominis25.  
The overall goals of this dissertation are to better understand drug treatment of T. 
vaginalis infection with metronidazole as well as factors that underpin the immune response to 
infection. In Chapter 2, identification of the protein targets as well as the adducted amino acid 
residues are explored using a more sensitive approach. The adaptation of a terminal alkyne 
analog of metronidazole allows the identification of more proteins than previously published and 
also demonstrate adducted cysteine residues for the first time. In Chapter 3, differences in 
cytokine elaborated from primary human monocytes exposed to a T. vaginalis strain with or 
without the endosymbiont M. hominis is explored. Together, these studies illuminate our 
knowledge of this important human pathogen, laying the foundation for potential exploration of 
future drug targets as well as providing insight into the observed range and severity of symptoms 
in infected patients. 
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Chapter 2 : Identification of novel protein targets of metronidazole in drug sensitive and 
resistant strains of Trichomonas vaginalis.  
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Abstract: 
Trichomonas vaginalis is an obligate, extracellular, flagellated protozoan parasite that 
causes the most common non-viral sexually transmitted infection, trichomoniasis. The infection 
is treated with 5-nitroimidazole drugs of which metronidazole (Mz) is the most widely used. 
Parasite death results from adduction of activated drug to proteins and consequent loss of 
function. While in use since 1960, known protein targets of the drug in T. vaginalis are limited. 
To identify the targets of Mz, we adapted a terminal alkyne analog of Mz (Mz-alkyne) that 
retains the capacity to be activated and to kill T. vaginalis. We determined that Mz-alkyne is able 
to bind to proteins in sensitive and resistant strains; that metronidazole binds to cysteine residues. 
We used a chemical labeling approach to identify more metronidazole protein targets in both a 
sensitive and resistant strain of the parasite, and found that more hydrogenosomal proteins are 
adducted in the Mz-sensitive strain. Furthermore, for the first time, we identify cysteine residues 
on some target proteins to which metronidazole adducts. 
 
Introduction: 
Trichomonas vaginalis is a microaerophilic protozoan parasite that causes trichomoniasis, 
the most common non-viral sexually transmitted infection worldwide1. Most of the estimated 
quarter billion annual infections2 are asymptomatic. However, symptomatic cases present as 
vaginitis and cervicitis in women and urethritis and prostatitis in men1.  
 5-nitroimidazole drugs metronidazole and tinidazole are the sole FDA-approved drugs for 
treating trichomoniasis3,4. Both are prodrugs and differ only in their side chains. Metronidazole 
(Mz), diffuses passively into cells5. Susceptible cells, including some anaerobic bacteria and 
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microaerophilic protozoans—like Trichomonas, Entamoeba, and Giardia—have the requisite 
redox potential to reduce Mz, and lack oxygen, which would otherwise regenerate the nontoxic-
parent compound, Mz6,7. Different redox pathways that reduce Mz to active metabolites are 
implicated in bacteria8 and protozoa6,9–11.  
 T. vaginalis contains an unusual organelle, called the hydrogenosome12, which is the site 
of carbohydrate catabolism, amino acid synthesis and Fe-S cluster assembly. While there is 
evidence that different hydrogenosomal processes reduce Mz in T. vaginalis7,9, evidence of 
cytosolic activation equally exists6,13. Previous work in T. vaginalis, E. histolytica, and G. 
lamblia identified seven, five, and eight Mz-adducted proteins, respectively, leading the authors 
to conclude that limited number of proteins are adducted to the drug6,10,11. Since activated Mz is 
an anion free radical14, and thus likely promiscuous, we hypothesize that there are more protein 
targets than previously reported6,10,11.   
In this work, we have adapted the use of an alkyne analog of metronidazole, Mz-
alkyne—which was synthesized and generously provided by Valery Fokin (University of 
Southern California) and Lars Eckmann (UCSD)—to functionally tag, potentially, the full 
complement of Mz targeted proteins in T. vaginalis. As terminal alkynes react specifically with 
azides under copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) “click” reaction15, target 
proteins can be bound by clicking to agarose-azide resin followed by enrichment. The resulting 
Mz targeted proteins were identified and quantified with tandem mass tag (TMT)-based 
proteomics. We have assessed target proteins in both metronidazole sensitive16,17 and resistant T. 
vaginalis. We report here the identification of 61 putative metronidazole targets between these 
metronidazole–sensitive and –resistant strains. In addition, we have been able to resolve the 
adducted cysteine residues on eight additional putative target proteins, bringing our total to 69 
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proteins, the highest reported in any such study. While cysteine, free and protein-bound, has been 
implicated in binding to activated metronidazole10,18, direct evidence for Mz binding to cysteine 
has not been reported until this study.  
 
Results: 
CuAAC enables detection of many T. vaginalis proteins adducted by Mz-alkyne 
Copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) is known to be specific 
between a terminal alkyne and an azide15, and given that a terminal alkyne analog of 
metronidazole (Mz-alkyne) is equally as trichomonocidal as the parent drug (Lars Eckmann, 
unpublished data), we first wanted to evaluate the specificity of Mz-alkyne adduction in 
Trichomonas vaginalis. To examine Mz-alkyne adduction in both metronidazole-sensitive and -
resistant strains, we used highly resistant strain B726817,19 as well as the drug sensitive, standard 
laboratory strain G316.  We treated metronidazole-sensitive strain G316 and -resistant strain 
B726817,19 parasites with 50 µM Mz, 50 µM Mz-alkyne, or DMSO. 300 µg of lysates were 
reacted with biotin-azide in 300 µl total CuAAC reaction, using sodium ascorbate as the 
reducing agent, for 1 hr. After incubation, 8 µg of reaction lysates were resolved by SDS-PAGE, 
and labeling was visualized by streptavidin blot. An antibody against T. vaginalis GAPDH 
served as a loading control (Fig. 2-1A). With DMSO-treated lysate reacted with biotin-azide as 
the background, we observed detection of multiple bands in Mz-alkyne-treated lysates from both 
G3 and B7268 parasites, equivalent to 3.6 fold and 2.8 fold increases over background, 
respectively (Fig. 2-1B). These data suggested that Mz-alkyne adduction might not be restricted 
to few proteins, as had been previously published6. We did not observe appreciable labeling over 
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background in CuAAC reactions with Mz-treated lysate or when Mz-alkyne-treated lysate 
CuAAC reaction lacked biotin-azide. As Mz has an alcohol handle instead of a terminal alkyne, 
the observation is in line with our expectation. Furthermore, observed adduction of Mz-alkyne to 
B7268 parasites (Fig. 2-1A), demonstrates that aerobic resistance, which is present in the 
parasite6,17 does not completely abrogate binding of activated Mz to target proteins. 
Mz-alkyne-treated parasites and CuAAC reaction allows identification of putative 
metronidazole targets in Mz-sensitive and -resistant parasites 
Having observed that proteins of different sizes are adducted by Mz-alkyne and can be 
detected by functionalizing the terminal alkyne handle to an azide-containing molecule, we next 
sought to determine the molecular identity of the proteins targeted by using Click-&-Go Protein 
Enrichment Kit for alkyne-modified proteins from Click Chemistry Tools (#1039) and following 
the enrichment scheme shown in (Fig. 2-2A). We used metronidazole-highly resistant strain 
B7268-Res17 and this strain expressing flavin reductase 1 (B7268-Sens) which results in >64X 
sensitivity to metronidazole17. T. vaginalis parasites were treated with Mz-alkyne or Mz-OH as a 
negative control. Following treatment, the parasites were lysed and the protein extracts subjected 
to click reaction with the agarose-azide resin. To eliminate non-specific binding of T. vaginalis 
proteins to the agarose resin, we reacted lysates from Mz-OH treatment. The beads were 
stringently washed to eliminate non-bound proteins and subjected to on-bead trypsin digestion, 
prior to TMT 10-plex labeling. For each strain, we performed TMT 10-plex labeling, according 
to manufacturer’s protocol, of equal peptides derived from biological triplicates of clicked Mz-
alkyne and Mz-OH “mock” reactions. All samples were then analyzed by tandem LC-MS/MS, 
and the spectra were searched against UniProt T. vaginalis sequences20 and a contaminant 
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database including proteins like trypsin and human keratins. A decoy database of reversed 
sequences was also included to estimate the false discovery rate. 
 Excluding proteins that were either decoys, contaminants, “only identified by site”, or 
matched by only a single peptide from quantitative analysis, 885 protein groups were identified 
in B7268-Res while 904 protein groups were identified in B7268-Sens. Abundance ratios of 
“click” vs “mock” were calculated for all protein groups and moderated t-test performed. As 
seen in the volcano plot of Log2 enrichment ratio versus -Log10 p-value, distribution of protein 
groups identified in B7268-Res and B7268-Sens in large part mirror each other (Fig. 2-2B). To 
determine protein groups that are putative targets of metronidazole, we selected those that are 
enriched (click/mock) at least two-fold and whose Benjamini and Hochberg adjusted p-value 
were less than 0.05 (boxed). This yielded 31 protein groups in B7268-Res and 39 protein groups 
in B7268-Sens, with 9 protein groups overlapping between the two strains.  
 
More hydrogenosomal targets of metronidazole identified in Mz-sensitive B7268-Sens than 
in Mz-resistant B7268-Res  
 Previous investigation of metronidazole targets in T. vaginalis using two-dimensional gel 
(2DE) identified seven cytosolic proteins, including thioredoxin reductase6. None of the seven 
were identified in this study; however, a thioredoxin reductase ortholog (TVAG_125360) with 
cytosolic and hydrogenosomal pattern of expression21, was identified in this study (Table 2-1). 
Thioredoxin reductase has been shown to be a key cytosolic activator of metronidazole6,13, and 
subsequent adduction of activated metronidazole decreases its activity6. 
13 
 
 Of the 31 proteins found in drug-resistant B7268-Res strain, only five of them—a small 
GTPase (TVAG_079570), Signal recognition particle subunit SRP72 (TVAG_039020), Clathrin 
heavy chain-related protein (TVAG_562550), a thioredoxin reductase (TVAG_125360), and a 
ribosomal protein (TVAG_128790)—(16.1%) have been published as hydrogenosomal proteins, 
with four coming from a proteome of the hydrogenosome22, and the other coming from a study of 
T. vaginalis thioredoxin reductases, which found TVAG_125360 to localize to the cytoplasm and 
hydrogenosome21. In contrast, 11 out of 39 protein groups (28.2%) identified in drug-sensitive 
B7268-Sens strain were previously published in the hydrogenosome proteome (Table 1).   
Broad single functional categorization of all 61 proteins showed that several pathways are 
affected by metronidazole (Fig. 2-3A & Fig. S1), with gene ontology annotations tabled in 
Supplementary Table 2-1. 9 proteins are shared between the proteomes from both strains (Fig. 2-
3B), and of them, only the ribosomal protein (TVAG_128790) is hydrogenosomal22 (Table 2-1). 
Functions were assigned in line with TrichDB annotation23, the published hydrogenosome 
proteome22, other studies21,24, UniProt20 and QuickGO25 gene ontology annotations, or Phyre2 
predictions26. 34.42% of all proteins are represented in the “other” and “unknown” functional 
grouping. Other functional groups include amino acid metabolism, energy metabolism, sugar 
metabolism, peptidases, translation, redox proteins, cytoskeletal proteins and hydrolases. 
Hydrolase classification include proteins annotated as hydrolases as well as phosphatases, which 
also perform similar reactions.   
 While the hydrogenosome was originally recognized as the canonical site of 
metronidazole activation27, more recent evidence has demonstrated that cytosolic enzymes play 
an important role in drug activation too6,13. Only 15 of the 61 putative targets identified have 
been identified as hydrogenosomal proteins21,22, (Fig. 2-3C). A machine learning algorithm was 
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developed to predict proteins that localize to the hydrogenosome based on the entire predicted 
protein-coding genes of T. vaginalis28. To evaluate the predictive value of using the model output 
scores28 to predict hydrogenosome localization of our identified putative targets, we determined 
the scores for published hydrogenosomal proteins22 (Table S2-2).  The machine learning 
algorithm was developed with the entire proteome of T. vaginalis taking into consideration 
proteins that had previously been shown to localize to the hydrogenosome28. In addition, because 
some hydrogenosome proteins have a targeting sequence while others do not21,22, two predictive 
scores based on presence of recognizable hydrogenosomal targeting signal sequence (HTS) 
(MOT+) and lack thereof (MOT-) were developed28. Scores and ranks from the algorithm were 
matched to the previously published hydrogenosomal proteome22 containing the 569 proteins 
with their accession numbers, annotation, functional group classification, presence of signal 
sequence and use in algorithm (Table S2-2). 94 of the 569 proteins had a MOT+ score ≥ 0.5 
while 75 of 569 had MOT- score ≥ 0.5. Interestingly, only 7 of the 15 hydrogenosomal 
proteins21,22 identified in our proteome had either score ≥ 0.5.  
Six new total proteins could be labeled as hydrogenosomal using either MOT+ ≥ 0.5 or 
MOT- score ≥ 0.5. Using MOT+ score ≥ 0.5, five other proteins could be predicted as 
hydrogenosomal including an alanyl-tRNA synthetase family protein (TVAG_299450), a 
cysteine synthase protein (TVAG_071080), two 2-deoxyglucose-6-phosphate phosphatases 
(TVAG_117360 & TVAG_417190), and an uncharacterized protein (TVAG_487100), which is 
also one of only two proteins with MOT- score ≥ 0.5. The other is another 2-deoxyglucose-6-
phosphate phosphatase (TVAG_463690). And of these six proteins, all three 2-deoxyglucose-6-
phosphate phosphatases were enriched in both B7268-Res and B7268-Sens. The uncharacterized 
protein TVAG_487100 was also enriched in both strains, while alanyl-tRNA synthetase family 
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protein (TVAG_299450) and cysteine synthase protein (TVAG_071080) were enriched only in 
B7268-Sens. Cytosolic alanyl-tRNA synthetases have been demonstrated to have mitochondrial 
localization in Saccharomyces cerevisiae and apicoplast localization in Plasmodium 
falciparum29, suggesting that T. vaginalis alanyl-tRNA synthetase could also have 
hydrogenosomal localization as predicted. Another annotated cysteine synthase protein was 
identified in the hydrogenosome proteome demonstrated cysteine metabolism in the 
hydrogenosome22. 
 Even with six more proteins predicted to localize to the hydrogenosome across both 
strains, the higher proportion in B7268-Sens (16/39) compared to B7268-Res (9/31) suggests 
that there is likely more hydrogenosomal drug activation in the Mz-sensitive strain, B7268-Sens, 
than in the Mz-resistant strain, B7268-Res. 
 
Mz decreases iodoacetamide alkyne (IAA) labeling of free cysteines and binds to cysteine 
residues 
Cysteine residues are reactive, and are targeted by many drugs in use including anti-
neoplastics, afatinib and ibrutinib, and antimicrobials showdomycin and leptomycin B30. 
Trichomonas vaginalis uses non-protein cysteine to scavenge for oxygen and maintain a 
microaerophilic environment17. In addition, when typical cysteine supplementation of culture 
medium is removed, parasites are more susceptible to lower concentration of metronidazole31. 
Moreover, canonical protein activators of metronidazole, ferredoxin and pyruvate ferredoxin 
oxidoreductase, as well as the cytosolic activator, thioredoxin reductase6, have reactive cysteine 
active sites. To test the hypothesis that metronidazole binds to cysteine residues, we employed an 
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activity-based protein profiling (ABPP) approach30. We treated parasites with 50 µM, 500 µM 
metronidazole and DMSO, as solvent control, for 1 hr. Thereafter, lysates were prepared and 
labeled with iodoacetamide alkyne (IAA). IAA, like iodoacetamide, readily labels reduced 
cysteine residues in proteins, and can be clicked to rhodamine-azide using CuAAC, and 
visualized by in-gel fluorescence (Fig. 2-4A). We observed decreased IAA labeling of lysates 
from Mz-treated parasites compared to lysates from DMSO control-treated parasites, with two-
fold reduction in IAA labeling in lysates from 50 µM Mz-treated parasites and four-fold 
reduction in IAA labeling in lysates from 500 µM Mz-treated parasites, suggesting that Mz 
adducts to cysteine residues on proteins. The observed labeling reduction was not due to amount 
of protein, as corresponding Coomassie staining of samples showed even loading (Fig. 2-4B). 
Interestingly, the highest prominent band on the gel corresponds to 55 kDa. While reports show 
that most T. vaginalis proteins are less than 70 kDa32, it is unclear why larger proteins detected 
by Coomassie staining were not labeled appreciable by IAA, especially in lysates from DMSO-
treated parasites. 
 
Mz-alkyne efficient labeling of proteins enables resolution of adducted cysteine residues 
Having identified protein targets and demonstrated that metronidazole adducts to cysteine 
residues, we wanted to identify the particular cysteine residues. In employing CuAAC click to 
agarose bead and on-bead digest, we were unable to resolve the amino acid residues to which 
Mz-alkyne adducted. Having demonstrated that Mz-alkyne binds to proteins in Mz-sensitive and 
-resistant parasites ~3-3.5 fold above background (Figs. 2-1A & 2-1B), we then quantified the 
binding to ensure that Mz-alkyne labeling was efficient enough to allow detection by mass 
spectrometry. To determine the efficiency of adduction by Mz-alkyne, we treated parasites with 
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50 µM Mz-alkyne, and subjected the lysate to CuAAC click to biotin-azide. DMSO control-
treated parasite lysate labeled with various concentrations of IAA and clicked to biotin-azide 
under the same conditions were also examined. We observed that Mz-alkyne adducts to proteins 
with a greater efficiency than labeling with 100 µM IAA, about 1.6x as intense (Figs. 2-5A & 2-
5B). This level of efficiency of labeling indicated that mass spec could be used to detect 
modified cysteine residues33,34. 
 Thereafter, lysates from Mz-sensitive parasites treated with 50 µM Mz-alkyne were 
subjected to CuAAC click to biotin-azide35. Samples were prepared using standard protocols for 
CuAAC enrichment36. Samples were purified after DTT reduction and iodoacetamide alkylation 
with single-pot, solid-phase-enhanced sample-preparation (SP3) beads37, and subjected to trypsin 
digest. Subsequent enrichment with neutrAvidin-agarose followed to obtain Mz-alkyne–
modified peptides. To identify modified cysteine residues, lysates from Mz-OH–treated parasites 
were standardly prepared without CuAAC click. Peptides were desalted and analyzed by LC-
MS/MS. Spectral searches were performed with IP2 ProLuCID. Using a differential modification 
search with fixed carbamidomethyl modification on cysteine, we expected a modification of 
400.19978 Da based on cysteine elimination of activated nitro group on Mz-alkyne38 and 
subsequent CuAAC with biotin-azide. We identified eight peptides corresponding to eight 
previously unidentified metronidazole target proteins (Table 2-2). Gene ontology annotation of 
these proteins are listed in Supplementary Table 2-3. None of these eight proteins was identified 
in the hydrogenosome proteome22; however, only dihydroorotate dehydrogenase family protein 
TVAG_186690 might be predicted to be hydrogenosomal with MOT+ score of 0.9998 and 
MOT- score of 0.888628. Interestingly, while localization of dihydroorotate dehydrogenase 
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family proteins can be cytosolic or mitochondrial39, previous investigation of pyrimidine 
metabolism in T. vaginalis concluded de novo pyrimidine synthesis to be absent in the parasite40.    
 
Discussion 
In this study, we have extended the use of copper(I)-catalyzed azide-alkyne cycloaddition 
(CuAAC) towards addressing three important issues: identifying metronidazole target proteins in 
Trichomonas vaginalis, determining whether metronidazole binds to cysteine, and demonstrating 
the cysteine residues adducted by the drug. Previously indirect evidence implicated cysteine 
involvement in drug binding10,18, however, this had not been definitively demonstrated, nor had 
particular residues been identified, as we have done here. 
 While the number of Mz-targeted proteins identified in total, 69, is over 9 times greater 
than the seven previously identified, it is likely that our adaptation failed to fully capture the 
number of proteins to which metronidazole binds. The Click Chemistry Tools kit (#1039) buffer 
with high urea and NaCl likely reduced the efficacy of CuAAC41. Most importantly, our results 
argue that metronidazole adducts widely and efficiently to proteins in the hydrogenosome and 
cytoplasm, a stark contrast to studies suggesting only a limited number of proteins6,10,11.  
 In a previous study, resistance to metronidazole could be induced with the use of a flavin 
inhibitor, which ultimately leads to loss of activity of thioredoxin reductase, a flavin enzyme13. In 
B7268-Res where flavin reductase activity is absent, one possibility might be that thioredoxin 
reductase after having activated some drug, loses its activity, as some of the activated drug also 
binds to the enzyme6. Thus, if there is loss of drug activation, then the parasites are able to resist 
even higher amount of drug, as seen in the B7268-Res strain. This would essentially mimic the 
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observed decreased uptake of metronidazole into non-susceptible cells42. Identified Mz protein 
targets in both sensitive and resistant parasites revealed commonalities and differences likely 
owing to net drug activation capabilities of the parasites. It is possible that where greater net drug 
activation is present, a sensitive strain, more proteins are able to be bound, thus increasing the 
likelihood of their disruption. 
 We identified cysteine residues adducted by Mz-alkyne in Mz-sensitive G3 parasites. 
These eight proteins were not identified in either of B7268-Res or B7268-Sens. This might have 
been due to proteome differences between the G3 strain and any of the B7268 strains used. For 
example, in a surface proteome analysis including G3 and B7268, there were notable differences 
in the proteins present as well as the relative abundance between strains43. 
 Moreover, further optimization and application of CuAAC to more Mz-resistant and -
sensitive strains might allow greater understanding of different pathways that are likely to be 
disrupted in treated parasites. In a parasite where few essential genes are known, this might be a 
valuable means to begin to gain a foothold in that regard. Furthermore, understanding of said 
essential pathways could hold the key for discovering pathways that might not yet be explored as 
druggable targets. 
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Materials and Methods: 
Growing cells 
The T. vaginalis strains used in this study were G3 (ATCC PRA-98), 
BRIS/92/STDL/B7268. B7268-Res and B7268-Sens were generated and characterized in a 
previous study17. Parasites were cultured in Diamond’s TYM medium supplemented with 10% 
horse serum (Sigma), 180 µM ferrous ammonium sulfate (Fisher), 28 µM sulfosalicylic acid 
(Fisher), 100 U/ml penicillin and 100 g/ml streptomycin (Thermo Fisher Scientific) (complete 
Diamond’s media)44. MasterNeo-(HA [hemagglutinin]) plasmid bearing TVAG_517010 (flavin 
reductase (FR)1)-Sens or empty vector control (EV)-Res was overexpressed17 and maintained 
with 100 g/ml of G418 (Gibco) for selection. Parasites were cultured at 37°C and passaged daily 
for 2 weeks or less. 
Metronidazole treatments 
Parasites were grown overnight in Complete Diamond medium without ascorbic acid, 
and washed with this media (3200 rpm 10 mins). 1 x 106 cells/ml parasites were seeded in tightly 
sealed plastic conical vials with complete Diamond (-ascorbic acid) with DMSO, as vehicle 
control, or Mz (or Mz-alkyne) as indicated. Parasites were incubated at 37 °C for 1-2 hrs, as 
indicated. Thereafter, parasites were washed with PBS (+5% sucrose) and lysed, sonicated 
(where indicated), and clarified by centrifugation at 14,000 rpm for 10 mins. 
Detection of proteins bound by Mz-alkyne 
300 µg of lysates in (2% SDS, 50 mM Tris, pH 7.5, 1x Halt Protease Inhibitor Cocktail 
(Thermo Fisher Scientific)) were CuAAC clicked to 31 µM biotin-azide (Cayman Chemical) in 
the presence of 2.5 mM THPTA (Sigma-Aldrich), 0.2 mM CuSO4 (Sigma-Aldrich) and 5 mM 
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Na-ascorbate (Sigma-Aldrich) in 300 µL total volume for 1 hr at room temp. Samples were 
prepared and heat-denatured at 95 °C for 5 mins, and 8 µg separated by SDS-PAGE. Gels were 
blotted onto PVDF membrane at 100 V for 1 hr. For Streptavidin detection of biotin-azide click 
to Mz-alkyne, membrane was blocked with 1% BSA in PBS for 30 mins, followed by incubation 
with 1:10,000 Streptavidin-HRP (Thermo Fisher Scientific) for 1 hr, washed three times with 
PBS, and detection. TvGAPDH was probed as loading control. Membrane was blocked with 5% 
milk in 1x TBST for 30 mins, followed by probing with 1:10,000 anti-TvGAPDH primary 
antibody (Cocalico Biologicals) for 1 hr, three 10-min washes with 1x TBST, 1:25,000 
horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (Jackson Laboratory) 
for 1 hr, and three 10-min washes with 1x TBST. Bio-Rad Gel Doc XR was used to capture 
images and ImageLab software (v. 5.1, Bio-Rad) used for analysis. 
Detection of Mz competition for cysteine residues, leading to decreased iodoacetamide 
alkyne (IAA) labeling 
200 µg of proteins from DMSO, 50 µM, or 500 µM Mz-treated parasites lysed in (1x 
PBS + 0.5% Triton X-100 + 2x Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific)) were 
labeled with 0, 10, or 100 µM IAA in 200 µL volume for 1 hr at room temp. Thereafter, 100 µg 
labeled samples were CuAAC clicked to 22.3 µM rhodamine-azide in the presence of 91 µM 
TBTA, 0.89 mM CuSO4 and 0.93 mM TCEP in 112 µL total volume for 1 hr at RT. Samples 
were prepared and heat-denatured at 95 °C for 5 mins, and 21 µg separated by SDS-PAGE. In-
gel fluorescence was visualized on a Bio-Rad Gel Doc XR using the 605/50 fluorescence filter. 
Detection of Mz-alkyne labeling efficiency  
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200 µg of proteins from DMSO-treated parasites lysed in (4% CHAPS, 1 M NaCl, 8 M 
Urea, 200 mM Tris pH 8, 2x Halt Protease Inhibitor Cocktail (Thermo Fisher Scientific)) were 
labeled with 0, 1, 10, or 100 µM IAA in 200 µL volume for 1 hr at room temp. After labeling, 
these IAA-labeled lysates as well as 200 µg lysate from Mz-alkyne-treated were CuAAC clicked 
to 0.38 mM biotin-azide in the presence of 4.25 mM THPTA, 0.425 mM CuSO4 and 4.25 mM 
Na-ascorbate in 235 µL total volume for 1 hr at RT. Samples were prepared and heat-denatured 
at 95 °C for 5 mins, and 20 µg separated by SDS-PAGE. Gels were blotted onto PVDF 
membrane at 100 V for 1 hr. For Streptavidin detection of biotin-azide click to Mz-alkyne, 
membrane was blocked with 1% BSA in PBS for 30 mins, followed by incubation with 1:10,000 
Streptavidin-HRP for 1 hr, washes with PBS, and detection. Bio-Rad Gel Doc XR was used to 
capture images and ImageLab software (v. 5.1, Bio-Rad) used for analysis. 
Mass spectrometry identification of Mz adducted proteins by quantitative proteomics.  
We adapted the Click-&-Go Protein Enrichment Kit for capture alkyne-modified proteins 
from Click Chemistry Tools (# 1039). Briefly, 500 µg of Mz-alkyne lysates lysed in (200 mM 
Tris pH 8, 4% CHAPS, 1 M NaCl, 8 M Urea, 1x Halt Protease Inhibitor Cocktail (Thermo Fisher 
Scientific)) were CuAAC clicked to agarose-azide beads overnight, rotating in a 30 °C chamber. 
Mock reaction with Mz-treated samples was also performed and samples were equally processed 
as below. The beads were washed with 1.8 mL water and then 1mL SDS wash buffer (100 mM 
Tris, 1% SDS, 250 mM NaCl, 5 mM EDTA, pH 8.0) before reduction with 10 mM DTT at 70 °C 
for 15 mins. After cooling, reduced proteins were subsequently alkylated with 80 mM 
iodoacetamide (incubated at room temp in the dark, rotating end-over-end for 30 mins). The 
reduced, alkylated resin-protein samples were transferred into 10 mL Bio-Rad Poly-Prep 30 
micron chromatography columns for washes. Each sample was washed with 55 mL SDS wash 
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buffer, then 55 mL 8 M urea/100 mM Tris pH 8, and finally 55 mL 20% acetonitrile. Resin-
protein samples were resuspended in digestion buffer (50 mM ammonium bicarbonate, 2 mM 
CaCl2, 10% acetonitrile), transferred to microcentrifuge tube, spun, and excess buffer removed. 5 
µL of 20 ng/µL trypsin was added and the samples incubated overnight in the dark at 37 °C. The 
resulting soluble fraction containing tryptic peptides was diluted to 1 mL before quenching the 
reaction with 2 µL trifluoroacetic acid. The acidified samples were dried in speed vac, 
resuspended in 0.2% formic acid and desalted by HPLC to desalt. The eluted samples from 
HPLC were dried in speed vac and resuspended in appropriate volume of 100 mM TEAB to 
achieve 0.25 ug/uL. Thermo TMT Label Reagents (# 90110) were equilibrated at room temp 
with anhydrous acetonitrile and 4.1 µL added to 2.5 ug peptides (10 µL). The reactions were 
incubated at room temp for 1 hr and subsequently quenched with 0.8 µL 5% hydroxylamine. 
Labeled samples were pooled together and desalted by HPLC. The elution was dried, 
resuspended and a fraction run on OrbiTrap Fusion (Thermo, Waltham MA) mass spectrometer. 
Digested peptides were loaded onto a 26-cm analytical HPLC column (75 μm inner 
diameter) packed in-house with ReproSil-Pur C18AQ 1.9-μm resin (120-Å pore size; Dr. Maisch, 
Ammerbuch, Germany). After loading, the peptides were separated with a 120-min gradient at a 
flow rate of 350 nl/min at 50°C (column heater) using the following gradient: 2–6% solvent B 
(7.5 min), 6–25% B (82.5 min), 25–40% B (30 min), 40–100% B (1 min), and 100% B (9 min), 
where solvent A was 97.8% H2O, 2% ACN, and 0.2% formic acid, and solvent B was 19.8% 
H2O, 80% ACN, and 0.2% formic acid. The Orbitrap Fusion was operated in data-dependent 
acquisition mode with SPS-MS3 to automatically switch between an MS1 scan (m/z = 400–
1500) in the Orbitrap (120,000 resolution), an MS2 scan using CID fragmentation and detection 
in the ion trap (with turbo scan rate), and an SPS-MS3 scan using HCD fragmentation (65 NCE 
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on the top 10 most intense MS2 ions) and detection in the Orbitrap (60,000 resolution). The 
automatic gain control (AGC) targets of the MS1, MS2, and MS3 scans were 4E5, 1E4, and 1E5, 
respectively. Monoisotopic precursor selection was enabled, as well as charge state filtering 
(only charge states 2-7, ignoring undetermined charge states), minimum intensity threshold of 
5000, and dynamic exclusion of 60 seconds. 
Data analysis for identification of Mz target proteins 
Thermo raw files were processed in MaxQuant with integrated search engine Andromeda 
(v. 1.6.10.43)45,46. Spectra were searched against UniProt T. vaginalis sequences (downloaded on 
1/30/2020, 50752 entries) and a contaminant database including proteins like trypsin and human 
keratins (246 entries). A decoy database of reversed sequences was also included to estimate the 
false discovery rate. Trypsin was the specified digestion enzyme and up to two missed cleavages 
were allowed. Methionine oxidation and protein N-terminal acetylation were specified as 
variable modifications. Carbamidomethylation of cysteine, and TMT10plex modification of 
peptide N-teminus and lysine were specified as fixed modification. Precursor mass tolerance was 
4.5ppm after mass recalibration, MS2 ion mass tolerance was 0.5 Da, and MS3 ion mass 
tolerance was 0.003 Da. Score thresholds were set to achieve a 1% false discovery rate at the 
protein, peptide, and peptide-spectrum match levels. Calculation of iBAQ values was enabled. 
Proteins that were either decoys, contaminants, “only identified by site”, or matched only a 
single peptide were not included in quantitative analysis. The remaining proteins were further 
analyzed using limma47, where a moderated t-test was performed between protein abundances in 
“clicked” samples and “mock” and “non-clicked” samples. Proteins whose 95% confidence 
interval of the abundance ratio indicated greater abundance in “clicked-enriched” than “mock 
enriched” and whose Benjamini and Hochberg adjusted p-value was less than 0.05 were 
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considered putative enriched targets of metronidazole. Selection criteria for targets: Log2 
(“clicked”/“mock”) ratio greater than or equal to 1 with adj. p-value less than 0.05. 
 
Sample preparation for site of labeling enrichment 
200 µL of MZ-alkyne treated lysates (1 mg/mL) was subjected to CuAAC click 
chemistry with 400 µM of biotin-azide in the presence of 100 µM of TBTA, 1 mM of CuSO4 and 
1 mM TCEP for 1 hr at RT. Heat denaturation at 95 °C for 5 mins followed after reaction. Each 
sample was treated with 0.5 µL benzonase and incubated at 37 °C for 30 mins. 10 mM DTT in 
water (10 µL of a 200 mM stock in water) was added into each sample and the sample was 
incubated at 65 °C for 15 mins. To this 20 mM iodoacetamide (10 µL of 400 mM iodoacetamide 
in water) was added and the solution/mixture was allowed to react at 37 °C for 30 mins with 
shaking. 
 Sera-Mag SpeedBeads Carboxyl Magnetic Beads (SP3) were purchased from GE 
Healthcare Life Sciences. SP3 was performed at a bead/protein ratio of 10:1 (wt/wt). For each 
200 µL lysates (1 mg/mL) sample, 20 µL of Sera-Mag SpeedBeads Carboxyl Magnetic Beads, 
hydrophobic (GE Healthcare, 65152105050250, 50 µg/µL, total 2mg) and 20 µL of Sera-Mag 
SpeedBeads Carboxyl Magnetic Beads, hydrophilic (GE Healthcare, 45152105050250, 50 
µg/µL, total 2 mg) were aliquoted into a single Eppendorf tube and gently mixed. The tube was 
placed on a magnetic rack until the beads settled to the tube wall, and the supernatant was 
removed. The beads were reconstituted in 400 μL of molecular biology grade (MB) water off the 
magnetic rack, mixed and supernatant was removed on the magnetic rack. The process was 
repeated for another two times before reconstituting the beads in 50 – 100 µL MB water. The 
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reconstituted bead solution was transferred to the CuAAC click sample containing 0.5% SDS, 
allowing to shake at 1200 rpm for 5 mins at room temp. To this, 400 µL of 100% EtOH was 
added and it was allowed to incubate for 5 mins at room temp with shaking at 1200 rpm. The 
sample was then placed on a magnetic rack until the beads settled on the tube wall. The 
supernatant was removed and discarded. SP3 beads were further washed three times with 400 µL 
of 80% EtOH, vortexed, magnetized and the supernatant was discarded. Beads were then 
resuspended in 100 µL PBS containing 2 M urea followed by the addition of 10 µL of trypsin 
solution (1 mg/mL). The digestion was allowed to proceed overnight at 37 ºC with shaking. 3 µL 
formic acid was added into the digested sample and incubated for 5 mins at room temp with 
shaking at 1200 rpm. To this was added ~ 2 mL acetonitrile (> 95% of the final volume) and the 
mixture was incubated at room temp for 10 mins with shaking. Magnetic rack was applied to 
separate beads from liquid, and the beads were washed with 500 µL acetonitrile for 3 times. 
Peptides were then eluted off from SP3 beads with 100 µL of 2% DMSO in MB water at 37 °C 
for 30 mins with shaking at 1200 rpm. 
NeutrAvidin enrichment of labeled peptides  
For each sample, 50 µL of neutrAvidin-agarose beads slurry (Pierce, 29200) was washed 
twice in 10 mL IAP buffer (522 mg MOPS, 146.1 mg Na2HPO4 and 70.98 mg NaCl in 50 mL 
MB water) and then resuspended in 500 µL IAP solution. The eluted peptide solution was 
transferred to the suspension of neutrAvidin-agarose beads and the mixture was nutated for 2 hrs 
at ambient temp. After incubation, the beads were pelleted down by centrifugation (1,4800 rpm, 
1 min) and washed (6 × 700 µL water). Bound peptides were eluted twice with 60 µL of 80% 
acetonitrile in MB water containing 0.1% formic acid (first at RT for 10 mins, second at 72 °C 
for 10 mins). After the first 10 mins incubation at RT, the sample was centrifuged (14,800 rpm, 1 
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min) and the top liquid layer was transferred into a Micro Bio-Spin columns with a receiving 
microcentrifuge tube and the bottom beads were then re-dissolved in 60 µL of 80% acetonitrile 
in water containing 0.1% formic acid. After the 10 min incubation at 72 °C, the mixture was 
transferred into the same bio-spin column. Elution was collected by centrifugation (14,800 rpm, 
1 min). The combined elution was dried by speed-vacuum and resuspended in 40 µL water 
containing 5% acetonitrile and 1% formic acid. Digested and neutrAvidin enriched peptides were 
separated on C18 reversed phase for proteomics identification. 
Mass spectrometry analysis for site of labeling peptides 
Samples were run on a QExactive Hybrid Orbitrap Mass Spectrometer (Thermo, 
Waltham MA) and spectra processed with IP2 ProLuCID. Carbamidomethylation of cysteine 
was specified as fixed modification. For Mz-alkyne-adducted cysteine residues, we hypothesized 
that adduct formation resulted from substitution of activated nitro group on the drug by 
nucleophilic sulfur anion, as previously published (Girard 1993). Based on differential 
modification, we searched for 400.19978 Da modification net difference on peptides with 
cysteine residues corresponding to the mass change attributable to Mz-alkyne CuAAC clicked to 
biotin-azide.  
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Figures and tables 
 
A 
 
B 
 
 
Figure 2-1. Biotin-azide labeling of protein lysate is Mz-alkyne-dependent. (A)Lysates were 
prepared from Mz-alkyne-, Mz-, and solvent-treated parasites. Lysates were clicked to biotin-
azide under Cu(I) catalysis. Streptavidin-HRP WB shows proteins of different sizes in lysates 
from Mz-alkyne-treated cells, but not in those from Mz-treated cells or Mz-alkyne-treated cells 
not subjected to bioin-azide click catalysis. These data suggest Mz-alkyne adducts to different T. 
vaginalis proteins, and that click reaction is specific. (B) Lane intensities were quantified with 
ImageJ. G3 = T. vaginalis strain G3 lysates. B7268 = T. vaginalis strain B7268 lysates. 
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Figure 2-2. Reaction scheme to enrich and identify Mz targets. (A) T. vaginalis parasites 
were incubated with Mz or Mz-alkyne for two hours. Lysate was prepared from treated cells and 
CuAAC “clicked” to azide agarose beads. Reacted lysate and beads were then stringently washed 
to remove unreacted proteins. Bead-bound proteins were digested on-bead with trypsin, and 
peptides were labeled and identified by LC/MS. (B) Using Thermo tandem mass tag (TMT) 10-
plex labeling for each strain, triplicates of peptides from Mz-alk “click” enrichment and Mz-OH 
mock enrichment were analyzed by LC-MS/MS. Protein groups demonstrating two-fold 
enrichment in click/mock with p-value < 0.05 are boxed in upper quadrant of graph. B7268-Res 
= drug resistant B7268 transfected with empty vector and B7268-Sens = drug sensitive B7268 
transfected with flavin reductase 117.  
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Strain Entry Gene names Protein names Functional group 
Unifying Functional 
Group Label 
Previous 
evidence for 
hyd  
localization22  
MOT
+ 
scorea 
MOT- 
scorea 
New 
hyd 
predb 
Res 
A2EF89 TVAG_079570 
Small GTP-
binding protein, 
putative 
Small GTPases 
and Associated 
Proteins 
Hydrolase Yes 0.0837 0.0002   
Res A2E5L3 TVAG_039020 
Signal recognition 
particle subunit 
SRP72  
ER (protein 
targeting) Other Yes 
     
0.0000  
  
0.0000    
Res A2GLT5 TVAG_562550 
Clathrin heavy 
chain-related 
protein  
Vesicle 
association Other Yes 
     
0.0000  
  
0.0001    
Res 
A2F9L1 TVAG_125360 
Thioredoxin 
reductase (EC 
1.8.1.9) 
Redox Redox Yes* 0.9999 0.9998   
Res 
A2DLA9 TVAG_267590 
WASH_WAHD 
domain-
containing 
proteinU 
Cytoskeletal 
Proteins Cytoskeleton   0 0   
Res 
A2FLD2 TVAG_057830 
WD_REPEATS_
REGION domain-
containing 
proteinU 
Cytoskeletal 
Proteins Cytoskeleton   0 0   
Res 
A2DAX3 TVAG_377820 
4Fe-4S binding 
domain 
containing 
proteinU 
Energy 
Metabolism Energy Metabolism   0 0   
Res 
A2E222 TVAG_463690 
2-deoxyglucose-
6-phosphate 
phosphatase, 
putative 
Hydrolase Hydrolase   0.245 0.9803  Yes  
Res A2DLV5 TVAG_462440 
Uncharacterized 
protein 
Hypothetical 
proteins  Unknown   0 0.0002   
Res A2EDW4 TVAG_363950 
Ankyrin repeat 
protein, putative 
Hypothetical 
proteins  Unknown   0.0003 0   
Res 
A2FRN2 TVAG_327610 
Ethanolamine-
phosphate 
cytidylyltransferas
e, putative 
Membrane 
lipid synthesis Other   0.0012 0.0132   
Res 
A2G214 TVAG_181540 
Clan CA, family 
C19, ubiquitin 
hydrolase-like 
cysteine peptidase 
Peptidases Peptidases   0.0235 0   
Res A2E3T7 TVAG_117470 
Thioredoxin 
family protein Redox Redox   0 0   
Res A2G881 TVAG_339630 
Thioredoxin 
family protein Redox Redox   0.0004 0   
Res 
A2E134 TVAG_388070 
Zinc finger, C2H2 
type family 
proteinU,O  
Ribosomal and 
Associated 
Proteins 
Ribosomal and 
Associated Proteins   0 0   
Res 
A2ER03 TVAG_016650 
RNA polymerase 
Rpb3/Rpb11 
dimerisation 
domain 
containing protein 
Transcription Other   0 0   
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Res A2DCT5 TVAG_237350 
KOG2701 
domain-
containing protein  
Golgi to 
plasma 
membrane 
transport Cytoskeleton   
     
0.0000  
  
0.0000    
Res A2DY82 TVAG_461080 
Nucleolar GTP-
binding protein 1 
Small GTPases 
and Associated 
Proteins/bioge
nesis of the 
60S ribosomal 
subunit Translation   
     
0.0001  
  
0.0000    
Res A2E6B9 TVAG_459140 
SnoRNA binding 
domain 
containing protein  
snoRNA 
binding Other   
     
0.0000  
  
0.0000    
Res A2EGV2 TVAG_497090 
Eukaryotic 
translation 
initiation factor, 
putative  
Translation 
initiation Translation   
9.30E-
10 
1.71E-
07   
Res A2EZW3 TVAG_273370 
Haloacid 
dehalogenase-like 
hydrolase family 
protein  Hydrolase Hydrolase   
     
0.0281  
  
0.0701    
Res A2EZW4 TVAG_273380 
6-
phosphogluconate 
dehydrogenase, 
decarboxylating  
Sugar 
Metabolism Sugar Metabolism   
     
0.0915  
  
0.5354    
Res & 
Sens A2E4D0 
TVAG_128790; 
TVAG_189110 
Ribosomal 
protein, putative 
Ribosomal and 
Associated 
Proteins 
Ribosomal and 
Associated Proteins Yes 0 0   
Res & 
Sens A2E3S6 TVAG_117360 
2-deoxyglucose-
6-phosphate 
phosphatase, 
putative 
Hydrolase Hydrolase   0.9759 0.0072  Yes  
Res & 
Sens A2F266 
TVAG_154750; 
TVAG_432360 
D-3-
phosphoglycerate 
dehydrogenaseO  
Amino Acid 
Metabolism 
Amino Acid 
Metabolism   0.0085 0.2978   
Res & 
Sens A2ESH7 TVAG_417190 
2-deoxyglucose-
6-phosphate 
phosphatase, 
putative 
Hydrolase Hydrolase   0.7388 0.009  Yes  
Res & 
Sens A2DZD8 TVAG_487100 
Uncharacterized 
protein 
Hypothetical 
proteins  Unknown   0.9998 0.9986  Yes  
Res & 
Sens A2EC21 TVAG_137880 
Peptidyl-prolyl 
cis-trans 
isomerase 
(PPIase) (EC 
5.2.1.8) 
Protein 
peptidyl-prolyl 
isomerization 
Other   0.0037 0.0122   
Res & 
Sens A2DGQ3 
TVAG_110520; 
TVAG_064320 
40S ribosomal 
protein S27 
Ribosomal and 
Associated 
Proteins 
Ribosomal and 
Associated Proteins   0 0   
Res & 
Sens A2DU34 TVAG_277930 
Uncharacterized 
protein 
Ubiquitin E3 
ligaseU Unknown   0.0081 0.0496   
Res & 
Sens A2GEF2 TVAG_414560 
dTDP-glucose 
4,6-dehydratase, 
putative 
Nucleoside 
sugar 
metabolism 
Other   0.0001 0   
Sens A2EIU6 TVAG_419720 
Aspartate 
aminotransferase, 
putative 
Amino Acid 
Metabolism 
Amino Acid 
Metabolism Yes 0.041 0.0217   
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Sens A2F0F6 TVAG_272760; TVAG_379130 
Dihydrolipoyl 
dehydrogenase 
(EC 1.8.1.4)U,O 
Amino Acid 
Metabolism 
Amino Acid 
Metabolism Yes 0.435 0.9999   
Sens A2D9B6 TVAG_183790 AP65-3 adhesin Energy Metabolism Energy Metabolism Yes 1 1   
Sens A2D900 TVAG_182620 TvhydB protein, putative 
Energy 
Metabolism Energy Metabolism Yes 1 0.9999   
Sens A2FCW4 TVAG_037570; TVAG_361590 
64kDa iron 
hydrogenase, 
putative 
Energy 
Metabolism Energy Metabolism Yes 0.998 0.0155   
Sens A2EVX8 TVAG_049830; TVAG_121610 
Pyridine 
nucleotide-
disulphide 
oxidoreductase 
family protein 
Flavin Proteins Redox Yes 0.7181 0.0745   
Sens A2EXK6 TVAG_260830 Uncharacterized protein 
Hypothetical 
proteins  Other Yes 0.002 0.0002   
Sens A2G591 TVAG_001130 Uncharacterized protein 
Hypothetical 
proteins  Other Yes 0 0.0003   
Sens A2FKA7 TVAG_293770 
Phosphofructokin
ase, putative 
Sugar 
Metabolism Sugar Metabolism Yes 0.4768 0.9551   
Sens A2DKI5 TVAG_190580 
Methionine 
aminopeptidase  Peptidases Peptidases Yes 
     
0.0000  
  
0.0000    
Sens A2ECT4 TVAG_276530; TVAG_071080 
Cysteine synthase, 
putative 
Amino Acid 
Metabolism 
Amino Acid 
Metabolism   0.9988 0.0403  Yes  
Sens A2EVS2 TVAG_299450 
Alanyl-tRNA 
synthetase family 
protein 
Amino Acid 
Metabolism 
Amino Acid 
Metabolism   0.9774 0.0519  Yes  
Sens A2G4A3 TVAG_374870 
Doublecortin 
domain-
containing 
proteinU 
Cytoskeletal 
Proteins Cytoskeleton   0.038 0.0007   
Sens A2DI20 TVAG_402650 Uncharacterized protein 
Cytoskeletal 
ProteinsU Cytoskeleton   0 0.0012   
Sens A2DFE0 TVAG_436920 
Quinoprotein 
alcohol 
dehydrogenase-
like 
Energy 
Metabolism Energy Metabolism   0 0   
Sens A2D7I8 TVAG_120430; TVAG_120280 
4-alpha-
glucanotransferas
e family protein 
Host Cell 
Adherence Other   0.1771 0.0003   
Sens A2DJ99 TVAG_136170 Paramyosin, putative 
Hypothetical 
proteins  Unknown   0 0   
Sens A2FNN7 TVAG_427040 
Cytosolic 
repetitive antigen, 
putativeU 
Hypothetical 
proteins  Unknown   0.0005 0   
Sens A2G7Q7 TVAG_100270 Uncharacterized protein 
Hypothetical 
proteins  Unknown   0 0   
Sens A2E8E3 TVAG_044950 
Uncharacterized 
protein 
Hypothetical 
proteins  Hydrolase   0.0022 0   
Sens A2E414 TVAG_074970 
Clan SC, family 
S33, 
methylesterase-
Peptidases Peptidases   0.0016 0   
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like serine 
peptidase 
Sens 
A2F507 TVAG_029150 
Clan CA, family 
C19, ubiquitin 
hydrolase-like 
cysteine peptidase 
Peptidases Peptidases   0.0002 0   
Sens 
A2DKZ3 TVAG_146890 
Serine/threonine-
protein 
phosphatase (EC 
3.1.3.16) 
Phosphatase Hydrolase   0 0   
Sens 
A2E6A2 TVAG_458970 
Translation 
initiation factor 
SUI1 family 
proteinU 
Ribosomal and 
Associated 
Proteins 
Ribosomal and 
Associated Proteins   0.0325 0.0001   
Sens 
A2EC78 TVAG_414060 
Glucose-6-
phosphate 1-
dehydrogenase 
(EC 1.1.1.49)U 
Sugar 
Metabolism Sugar Metabolism   0.0295 0.0291   
Sens A2E7M9 TVAG_344080 
AP-1 complex 
subunit gamma  
Vesicle 
mediated 
transport Other   
     
0.0012  
  
0.0000    
Sens A2E2S0 TVAG_212800 
Clan MG, familly 
M24, 
aminopeptidase P-
like 
metallopeptidase  Peptidases Peptidases   
     
0.0020  
  
0.0001    
Sens A2E347 TVAG_405290 
Dentin 
sialophosphoprote
in, putative  
Hypothetical 
proteins Unknown   
     
0.0000  
  
0.0000    
Sens A2ERT0 TVAG_227780 
Uncharacterized 
protein  
Hypothetical 
proteins  Unknown   
     
0.0000  
  
0.0000    
Sens A2FDI8 TVAG_315190 
CAMK family 
protein kinase  Kinase Other   
     
0.0008  
  
0.0000    
 
Table 2-1. Analysis of putative protein targets identified by Mz-alkyne. Displayed in the 
table are the 61 unique protein groups identified as putative targets by our selection criteria of 
two-fold increase in click over mock at p-value < 0.5. In light blue background are the 22 
proteins found to be enriched only in B7268-Res strain, while the 9 proteins on green 
background are the proteins identified in both Res and Sens strains. And the 30 proteins on 
yellow background are proteins enriched significantly in only the Sens strain. Annotation of 
protein names are primarily from TrichDB23, with some annotation coming from UniProt20 and 
OrthoMCL48 databases, as indicated. Functional group was assigned based on gene ontology 
classifications from UniProt20 and QuickGO25. Unifying functional group label was assigned to 
help functionally categorize Mz-alkyne adducted proteins (Fig. 2-3A). As the hydrogenosome is 
canonically important in metronidazole activation, evaluating how many target proteins are 
hydrogenosomal is important in gleaning potential differences in drug activation in different 
strains. Of the 61 identified proteins, 14 were found in a previously published proteome22 of the 
organelle while an additional protein, thioredoxin reductase, marked with an asterisk (*) was 
identified to dually localize to the cytoplasm and hydrogenosome21. To determine if more of the 
adducted proteins were likely hydrogenosomal proteins that were not identified previously, we 
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obtained the predicted hydrogenosomal scores from a previous machine learning study of 
hydrogenosomal proteins28. Selecting a predictive score of ≥ 0.7000, six additional proteins 
predicted to be hydrogenosomal, bringing the potential tally to 21 of 61 proteins, 34%, up from 
24.5%.  
a MOT+ & MOT- scores from: Burstein D, Gould SB, Zimorski V, et al. A machine learning approach to 
identify hydrogenosomal proteins in trichomonas vaginalis. Eukaryot Cell. 2012;11(2):217-228. 
doi:10.1128/EC.05225-11  
b Prediction of hydrogenosomal localization from MOT+ & MOT- ≥ 0.7000 
U Putative identities from UniProt database: D506-D515. UniProt: a worldwide hub of protein knowledge 
The UniProt Consortium. Nucleic Acids Res. 2019;47. doi:10.1093/nar/gky1049 
O Putative identities from OrthoMCL database: Fischer S, Brunk BP, Chen F, et al. Using OrthoMCL to 
Assign Proteins to OrthoMCL-DB Groups or to Cluster Proteomes Into New Ortholog Groups. In: Current 
Protocols in Bioinformatics. Vol 35. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2011:6.12.1-6.12.19. 
doi:10.1002/0471250953.bi0612s35 
* Mentel M, Zimorski V, Haferkamp P, Martin W, Henze K. Protein import into hydrogenosomes of 
Trichomonas vaginalis involves both N-terminal and internal targeting signals: A case study of thioredoxin 
reductases. Eukaryot Cell. 2008;7(10):1750-1757. doi:10.1128/EC.00206-08  
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Figure 2-3. Mz targets in Mz-sensitive & -resistant parasites. (A) Broad functional categories 
of all 61 proteins are represented. Only seven proteins were identified in a previous study6, with 
sugar metabolism and redox being the only represented functional category. In contrast, proteins 
identified in this study belong to more functional categories. 34% of all proteins are represented 
in the “other” and “unknown” functional grouping. (B) More proteins were identified in B7268-
Sens than in B7268-Res. 9 identified proteins are shared between both strains. (C) Most proteins 
identified are predicted to be cytoplasmic. A quarter of all targets are hydrogenosomal proteins. 
Of the 12 classified as hydrogenosomal proteins, 11 were previously identified in a published 
hydrogenosomal proteome, and one, a thioredoxin reductase ortholog, was published in a 
separate report. 
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Figure 2-4. Increasing Mz concentration increasingly decreases IAA binding to cysteine 
residues. (A) Using activity-based protein profiling (ABPP) to evaluate if Mz treatment of 
parasites decreases the labeling efficiency of IAA, which labels free cysteines. Parasites are 
treated with DMSO, 50 µM Mz, or 500 µM Mz, and lysates prepared. Equal lysates are labeled 
with IAA as indicated, followed by CuAAC click to rhodamine-azide, and SDS-PAGE. As 
observed, on in-gel imaging, 50 µM Mz decreased IAA labeling two-fold and 500 µM Mz 
further decreased IAA labeling. Decreased labeling suggests that Mz reduces free cysteines, 
likely through binding to them. (B) There is even loading of protein samples, as observed on 
Coomassie staining, indicating that the observation of decreased IAA labeling in Mz-treated 
lysates is not due to protein loading differences. (C) Lane intensities were quantified with ImageJ 
and plotted relative to maximal IAA labeling, DMSO:100 µM IAA. Labels = Mz treatment:IAA 
concentration. 
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Figure 2-5. Mz-alkyne efficiently labels cysteine residues and allows for identification for 
drug-adduction sites.  (A) 50 µM Mz-alkyne – treated lysate was CuAAC clicked to biotin-
azide and compared to lysates from DMSO-treated parasites that were subsequently treated with 
different concentrations of IAA before CuAAC click to biotin-azide. 20 µg of each reaction was 
resolved by SDS-PAGE and streptavidin blotting was used to detect CuAAC biotin coupling. 
Compared to 100 µM IAA labeling of DMSO lysate, 50 µM Mz-alkyne labeled lysates are 1.6x 
more intense, as seen in (B).   
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Table 2-2. Peptides containing identified cysteine residues. To detect modified amino acid 
residues on Mz target proteins, lysates from Mz-alkyne were CuAAC clicked to biotin-azide and 
following established protocol36, peptides were run on Thermo QExactive Hybrid Orbitrap Mass 
Spectrometer. Peptide search was performed with IP2 ProLuCID and searching for differential 
modification of 400.19978 Da on cysteine residues, here highlighted in red. Eight peptides were 
identified and correspond to eight previously unidentified target proteins. Adducted residues and 
peptides are shown. Protein names and predicted functional grouping are based on UniProt20. Of 
the eight proteins identified, only one protein highlighted in green is predicted to have 
hydrogenosomal localization, having MOT+ score of 0.9998 and MOT- score of 0.8886. The 
other seven proteins are predicted to be cytosolic proteins.  
 
U Protein names and Predicted Functional Group from UniProt database: D506-D515. UniProt: a 
worldwide hub of protein knowledge The UniProt Consortium. Nucleic Acids Res. 2019;47. 
doi:10.1093/nar/gky1049 
 
 
 
 
 
  
UniPr
ot  
Gene 
names Protein namesU 
Predicted 
Functiona
l GroupU Length 
Peptides identified (# correspond to first and last AA 
in peptide) Residue 
A2EC2
5 
TVAG_137
920 Profilin 
Actin 
binding 123 92 – VVVISVCGGGKPQIEAKNQVFNVAK – 116 Cys98 
A2DC3
4 
TVAG_457
100 
Uncharacterized 
protein 
Centrosome
-associated 1051 878 – QLEIPITNFTSQKIVVDVECLDGKH – 902 Cys897 
A2DG7
6 
TVAG_163
990 
Beige/BEACH 
domain containing 
protein Unknown 1219 1020 – LVVCGSDCFIYLWNSMTS – 1037 Cys1027 
A2FQA
9 
TVAG_186
690 
Dihydroorotate 
dehydrogenase 
family protein 
Oxidoreduct
ase 268 
209 – 
QTKPPKVIEDNCVGCSQCELSCCYDAIKVVNAVAKVTPE
KCFK – 251 Cys231 
A2E6I9 
TVAG_487
960 
AGC family protein 
kinase Kinase 393 1 – MDDEEITCIPIGNYILRQRIGEGAFSSVW – 29 Cys8 
A2EW
S6 
TVAG_169
080 
Ankyrin repeat 
protein, putative Unknown 745 
286 – 
SAQMNVLHIASYYGNTDVCKIILNSSVDYHPLINAKGLY
KQTPLHFASR – 334 Cys304 
A2DU
C4 
TVAG_262
120 
ANK_REP_REGION 
domain-containing 
protein Unknown 700 
277 – 
GIITKQSFPSCDIYQYIIEKSYSKMALLCFKYFPDLEFTND 
– 317  Cys305 
A2EP
M0 
TVAG_130
970 
WD_REPEATS_RE
GION domain-
containing protein 
Microtubule 
severing 550 270 – DLCVAQNEITIASTEK – 285  Cys272 
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Supplementary figure and tables 
 
 
 
Supplementary Figure 2-1. Many cellular processes are affected by Mz-alkyne in both 
strains. Word cloud visualization of the functional group classification of all 61 target proteins 
shows that more proteins fall in the hypothetical proteins category than any other. Moreover, this 
suggests that trichomonocidal effect of metronidazole is likely secondary to failure of multiple 
pathways.    
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GENE 
PRODUCT 
ID SYMBOL GENE_PRODUCT_NAME QUALIFIER GO TERM GO NAME 
A2D7I8 TVAG_120430 
4-alpha-glucanotransferase 
family protein involved_in GO:0005975 carbohydrate metabolic process 
A2D7I8 TVAG_120430 
4-alpha-glucanotransferase 
family protein enables GO:2001070 starch binding 
A2D7I8 TVAG_120430 
4-alpha-glucanotransferase 
family protein enables GO:0004134 4-alpha-glucanotransferase activity 
A2D7I8 TVAG_120430 
4-alpha-glucanotransferase 
family protein enables GO:0030246 carbohydrate binding 
A2D7I8 TVAG_120430 
4-alpha-glucanotransferase 
family protein enables GO:0016740 transferase activity 
A2D7I8 TVAG_120430 
4-alpha-glucanotransferase 
family protein involved_in GO:0005977 glycogen metabolic process 
A2D900 TVAG_182620 TvhydB protein, putative enables GO:0051539 4 iron, 4 sulfur cluster binding 
A2D900 TVAG_182620 TvhydB protein, putative enables GO:0005506 iron ion binding 
A2D900 TVAG_182620 TvhydB protein, putative involved_in GO:0055114 oxidation-reduction process 
A2D900 TVAG_182620 TvhydB protein, putative enables GO:0008901 ferredoxin hydrogenase activity 
A2D900 TVAG_182620 TvhydB protein, putative enables GO:0051536 iron-sulfur cluster binding 
A2D9B6 TVAG_183790 AP65-3 adhesin enables GO:0004473 malate dehydrogenase (decarboxylating) (NADP+) activity 
A2D9B6 TVAG_183790 AP65-3 adhesin enables GO:0004470 malic enzyme activity 
A2D9B6 TVAG_183790 AP65-3 adhesin involved_in GO:0006108 malate metabolic process 
A2D9B6 TVAG_183790 AP65-3 adhesin involved_in GO:0006090 pyruvate metabolic process 
A2D9B6 TVAG_183790 AP65-3 adhesin enables GO:0004470 malic enzyme activity 
A2D9B6 TVAG_183790 AP65-3 adhesin involved_in GO:0055114 oxidation-reduction process 
A2D9B6 TVAG_183790 AP65-3 adhesin enables GO:0004471 malate dehydrogenase (decarboxylating) (NAD+) activity 
A2D9B6 TVAG_183790 AP65-3 adhesin enables GO:0051287 NAD binding 
A2D9B6 TVAG_183790 AP65-3 adhesin enables GO:0046872 metal ion binding 
A2DAX3 TVAG_377820 
4Fe-4S binding domain 
containing protein enables GO:0009055 electron transfer activity 
A2DAX3 TVAG_377820 
4Fe-4S binding domain 
containing protein enables GO:0051536 iron-sulfur cluster binding 
A2DAX3 TVAG_377820 
4Fe-4S binding domain 
containing protein involved_in GO:0022900 electron transport chain 
A2DCT5 TVAG_237350 
KOG2701 domain-containing 
protein involved_in GO:0006893 Golgi to plasma membrane transport 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 involved_in GO:0000028 ribosomal small subunit assembly 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 enables GO:0003723 RNA binding 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 enables GO:0003735 structural constituent of ribosome 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 part_of GO:0022627 cytosolic small ribosomal subunit 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 part_of GO:0005840 ribosome 
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A2DGQ3 TVAG_110520 40S ribosomal protein S27 involved_in GO:0006412 translation 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 enables GO:0003735 structural constituent of ribosome 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 part_of GO:0005840 ribosome 
A2DGQ3 TVAG_110520 40S ribosomal protein S27 enables GO:0046872 metal ion binding 
A2DKI5 TVAG_190580 Methionine aminopeptidase enables GO:0004177 aminopeptidase activity 
A2DKI5 TVAG_190580 Methionine aminopeptidase involved_in GO:0006508 proteolysis 
A2DKI5 TVAG_190580 Methionine aminopeptidase enables GO:0008235 metalloexopeptidase activity 
A2DKI5 TVAG_190580 Methionine aminopeptidase enables GO:0004177 aminopeptidase activity 
A2DKI5 TVAG_190580 Methionine aminopeptidase enables GO:0046872 metal ion binding 
A2DKI5 TVAG_190580 Methionine aminopeptidase enables GO:0016787 hydrolase activity 
A2DKI5 TVAG_190580 Methionine aminopeptidase enables GO:0008233 peptidase activity 
A2DKI5 TVAG_190580 Methionine aminopeptidase involved_in GO:0006508 proteolysis 
A2DKI5 TVAG_190580 Methionine aminopeptidase part_of GO:0005737 cytoplasm 
A2DKI5 TVAG_190580 Methionine aminopeptidase part_of GO:0005737 cytoplasm 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase enables GO:0004722 protein serine/threonine phosphatase activity 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase part_of GO:0005634 nucleus 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase part_of GO:0005737 cytoplasm 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase enables GO:0016787 hydrolase activity 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase enables GO:0016787 hydrolase activity 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase enables GO:0004721 phosphoprotein phosphatase activity 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase enables GO:0046872 metal ion binding 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase enables GO:0004721 phosphoprotein phosphatase activity 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase involved_in GO:0006470 protein dephosphorylation 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase involved_in GO:0006470 protein dephosphorylation 
A2DKZ3 TVAG_146890 
Serine/threonine-protein 
phosphatase involved_in GO:0006470 protein dephosphorylation 
A2DLA9 TVAG_267590 
WASH_WAHD domain-
containing protein involved_in GO:0034314 Arp2/3 complex-mediated actin nucleation 
A2DLA9 TVAG_267590 
WASH_WAHD domain-
containing protein part_of GO:0071203 WASH complex 
A2DLA9 TVAG_267590 
WASH_WAHD domain-
containing protein part_of GO:0005769 early endosome 
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A2DLA9 TVAG_267590 
WASH_WAHD domain-
containing protein enables GO:0043014 alpha-tubulin binding 
A2DU34 TVAG_277930 Uncharacterized protein part_of GO:0016020 membrane 
A2DU34 TVAG_277930 Uncharacterized protein part_of GO:0016021 integral component of membrane 
A2DY82 TVAG_461080 
Nucleolar GTP-binding 
protein 1 enables GO:0005525 GTP binding 
A2DY82 TVAG_461080 
Nucleolar GTP-binding 
protein 1 part_of GO:0005730 nucleolus 
A2DY82 TVAG_461080 
Nucleolar GTP-binding 
protein 1 involved_in GO:0042254 ribosome biogenesis 
A2DY82 TVAG_461080 
Nucleolar GTP-binding 
protein 1 part_of GO:0005634 nucleus 
A2DY82 TVAG_461080 
Nucleolar GTP-binding 
protein 1 part_of GO:0005730 nucleolus 
A2E134 TVAG_388070 
Zinc finger, C2H2 type family 
protein part_of GO:0030687 preribosome, large subunit precursor 
A2E134 TVAG_388070 
Zinc finger, C2H2 type family 
protein involved_in GO:0042273 ribosomal large subunit biogenesis 
A2E222 TVAG_463690 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016791 phosphatase activity 
A2E222 TVAG_463690 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2E222 TVAG_463690 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2E222 TVAG_463690 
Haloacid dehalogenase-like 
hydrolase family protein involved_in GO:0016311 dephosphorylation 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase enables GO:0042393 histone binding 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase part_of GO:0035101 FACT complex 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase involved_in GO:0032968 
positive regulation of transcription elongation from RNA polymerase 
II promoter 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase involved_in GO:0034724 DNA replication-independent nucleosome organization 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase enables GO:0031491 nucleosome binding 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase involved_in GO:0006368 transcription elongation from RNA polymerase II promoter 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase part_of GO:0035101 FACT complex 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase enables GO:0004177 aminopeptidase activity 
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A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase involved_in GO:0006281 DNA repair 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase part_of GO:0035101 FACT complex 
A2E2S0 TVAG_212800 
Clan MG, familly M24, 
aminopeptidase P-like 
metallopeptidase involved_in GO:0006508 proteolysis 
A2E347 TVAG_405290 
Dentin sialophosphoprotein, 
putative part_of GO:0016021 integral component of membrane 
A2E347 TVAG_405290 
Dentin sialophosphoprotein, 
putative part_of GO:0016020 membrane 
A2E3S6 TVAG_117360 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016791 phosphatase activity 
A2E3S6 TVAG_117360 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2E3S6 TVAG_117360 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2E3S6 TVAG_117360 
Haloacid dehalogenase-like 
hydrolase family protein involved_in GO:0016311 dephosphorylation 
A2E3T7 TVAG_117470 
Thioredoxin domain-
containing protein part_of GO:0005783 endoplasmic reticulum 
A2E3T7 TVAG_117470 
Thioredoxin domain-
containing protein involved_in GO:0045454 cell redox homeostasis 
A2E414 TVAG_074970 
Hydrolase_4 domain-
containing protein enables GO:0016298 lipase activity 
A2E414 TVAG_074970 
Hydrolase_4 domain-
containing protein part_of GO:0016020 membrane 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein part_of GO:0022625 cytosolic large ribosomal subunit 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein enables GO:0003735 structural constituent of ribosome 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein enables GO:0003723 RNA binding 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein part_of GO:0005840 ribosome 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein involved_in GO:0006412 translation 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein enables GO:0003735 structural constituent of ribosome 
A2E4D0 TVAG_128790 
Ribos_L4_asso_C domain-
containing protein part_of GO:0005840 ribosome 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 contributes_to GO:0043022 ribosome binding 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 enables GO:0008312 7S RNA binding 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 involved_in GO:0006614 SRP-dependent cotranslational protein targeting to membrane 
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A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 part_of GO:0005786 signal recognition particle, endoplasmic reticulum targeting 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 involved_in GO:0006614 SRP-dependent cotranslational protein targeting to membrane 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 enables GO:0008312 7S RNA binding 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 part_of GO:0048500 signal recognition particle 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 part_of GO:0005786 signal recognition particle, endoplasmic reticulum targeting 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 part_of GO:0005737 cytoplasm 
A2E5L3 TVAG_039020 
Signal recognition particle 
subunit SRP72 part_of GO:0005737 cytoplasm 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein involved_in GO:0001731 formation of translation preinitiation complex 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein involved_in GO:0002188 translation reinitiation 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein enables GO:0003729 mRNA binding 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein enables GO:0003743 translation initiation factor activity 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein involved_in GO:0006413 translational initiation 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein enables GO:0003743 translation initiation factor activity 
A2E6A2 TVAG_458970 
SUI1 domain-containing 
protein involved_in GO:0006413 translational initiation 
A2E6B9 TVAG_459140 
Nop domain-containing 
protein part_of GO:0031428 box C/D snoRNP complex 
A2E6B9 TVAG_459140 
Nop domain-containing 
protein part_of GO:0032040 small-subunit processome 
A2E6B9 TVAG_459140 
Nop domain-containing 
protein enables GO:0030515 snoRNA binding 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma enables GO:0035615 clathrin adaptor activity 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma enables GO:0140312 cargo adaptor activity 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0030121 AP-1 adaptor complex 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma involved_in GO:0006898 receptor-mediated endocytosis 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma involved_in GO:0006896 Golgi to vacuole transport 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0005794 Golgi apparatus 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma involved_in GO:0016192 vesicle-mediated transport 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma involved_in GO:0006886 intracellular protein transport 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0030117 membrane coat 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0030121 AP-1 adaptor complex 
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A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0005794 Golgi apparatus 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0031410 cytoplasmic vesicle 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0016020 membrane 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma involved_in GO:0015031 protein transport 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma part_of GO:0005737 cytoplasm 
A2E7M9 TVAG_344080 AP-1 complex subunit gamma involved_in GO:0006886 intracellular protein transport 
A2E8E3 TVAG_044950 Uncharacterized protein part_of GO:0016021 integral component of membrane 
A2E8E3 TVAG_044950 Uncharacterized protein part_of GO:0016020 membrane 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase part_of GO:0005737 cytoplasm 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase involved_in GO:0000413 protein peptidyl-prolyl isomerization 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0003755 peptidyl-prolyl cis-trans isomerase activity 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase involved_in GO:0006457 protein folding 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0016018 cyclosporin A binding 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase involved_in GO:0000413 protein peptidyl-prolyl isomerization 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0003755 peptidyl-prolyl cis-trans isomerase activity 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase involved_in GO:0006457 protein folding 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0003755 peptidyl-prolyl cis-trans isomerase activity 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0016853 isomerase activity 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0003755 peptidyl-prolyl cis-trans isomerase activity 
A2EC21 TVAG_137880 
Peptidyl-prolyl cis-trans 
isomerase enables GO:0003755 peptidyl-prolyl cis-trans isomerase activity 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0005975 carbohydrate metabolic process 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0006006 glucose metabolic process 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0006098 pentose-phosphate shunt 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase enables GO:0017057 6-phosphogluconolactonase activity 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase enables GO:0050661 NADP binding 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0055114 oxidation-reduction process 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase enables GO:0004345 glucose-6-phosphate dehydrogenase activity 
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A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase enables GO:0016614 oxidoreductase activity, acting on CH-OH group of donors 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0005975 carbohydrate metabolic process 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0055114 oxidation-reduction process 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0006006 glucose metabolic process 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase enables GO:0016491 oxidoreductase activity 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase enables GO:0004345 glucose-6-phosphate dehydrogenase activity 
A2EC78 TVAG_414060 
Glucose-6-phosphate 1-
dehydrogenase involved_in GO:0006098 pentose-phosphate shunt 
A2ECT4 TVAG_276530 
PALP domain-containing 
protein enables GO:0004124 cysteine synthase activity 
A2ECT4 TVAG_276530 
PALP domain-containing 
protein enables GO:0030170 pyridoxal phosphate binding 
A2ECT4 TVAG_276530 
PALP domain-containing 
protein part_of GO:0005737 cytoplasm 
A2ECT4 TVAG_276530 
PALP domain-containing 
protein involved_in GO:0006535 cysteine biosynthetic process from serine 
A2EF89 TVAG_079570 
Small GTP-binding protein, 
putative involved_in GO:0006886 intracellular protein transport 
A2EF89 TVAG_079570 
Small GTP-binding protein, 
putative enables GO:0003924 GTPase activity 
A2EF89 TVAG_079570 
Small GTP-binding protein, 
putative part_of GO:0012505 endomembrane system 
A2EF89 TVAG_079570 
Small GTP-binding protein, 
putative enables GO:0003924 GTPase activity 
A2EF89 TVAG_079570 
Small GTP-binding protein, 
putative enables GO:0005525 GTP binding 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative enables GO:0003729 mRNA binding 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative part_of GO:0005730 nucleolus 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative part_of GO:0071013 catalytic step 2 spliceosome 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative enables GO:0003723 RNA binding 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative enables GO:0003724 RNA helicase activity 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative enables GO:0003676 nucleic acid binding 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative enables GO:0005524 ATP binding 
A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative enables GO:0003743 translation initiation factor activity 
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A2EGV2 TVAG_497090 
Eukaryotic translation 
initiation factor, putative involved_in GO:0006413 translational initiation 
A2EIU6 TVAG_419720 
Aminotran_1_2 domain-
containing protein involved_in GO:0009058 biosynthetic process 
A2EIU6 TVAG_419720 
Aminotran_1_2 domain-
containing protein enables GO:0030170 pyridoxal phosphate binding 
A2EIU6 TVAG_419720 
Aminotran_1_2 domain-
containing protein enables GO:0003824 catalytic activity 
A2EIU6 TVAG_419720 
Aminotran_1_2 domain-
containing protein enables GO:0016740 transferase activity 
A2EIU6 TVAG_419720 
Aminotran_1_2 domain-
containing protein enables GO:0008483 transaminase activity 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein part_of GO:0005736 RNA polymerase I complex 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein contributes_to GO:0001054 RNA polymerase I activity 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein part_of GO:0005666 RNA polymerase III complex 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein contributes_to GO:0003899 DNA-directed 5'-3' RNA polymerase activity 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein contributes_to GO:0001056 RNA polymerase III activity 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein enables GO:0003899 DNA-directed 5'-3' RNA polymerase activity 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein involved_in GO:0006351 transcription, DNA-templated 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein enables GO:0046983 protein dimerization activity 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein involved_in GO:0006383 transcription by RNA polymerase III 
A2ER03 TVAG_016650 
RPOLD domain-containing 
protein involved_in GO:0006360 transcription by RNA polymerase I 
A2ESH7 TVAG_417190 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016791 phosphatase activity 
A2ESH7 TVAG_417190 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2ESH7 TVAG_417190 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2ESH7 TVAG_417190 
Haloacid dehalogenase-like 
hydrolase family protein involved_in GO:0016311 dephosphorylation 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0002161 aminoacyl-tRNA editing activity 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0004813 alanine-tRNA ligase activity 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0016597 amino acid binding 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0005524 ATP binding 
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A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein involved_in GO:0006400 tRNA modification 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein involved_in GO:0006419 alanyl-tRNA aminoacylation 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0004812 aminoacyl-tRNA ligase activity 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0004813 alanine-tRNA ligase activity 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein involved_in GO:0043039 tRNA aminoacylation 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0000166 nucleotide binding 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0003676 nucleic acid binding 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0005524 ATP binding 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein part_of GO:0005737 cytoplasm 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein involved_in GO:0006419 alanyl-tRNA aminoacylation 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein enables GO:0004812 aminoacyl-tRNA ligase activity 
A2EVS2 TVAG_299450 
AA_TRNA_LIGASE_II_ALA 
domain-containing protein involved_in GO:0106074 aminoacyl-tRNA metabolism involved in translational fidelity 
A2EVX8 TVAG_049830 
Pyridine nucleotide-disulphide 
oxidoreductase family protein enables GO:0005506 iron ion binding 
A2EVX8 TVAG_049830 
Pyridine nucleotide-disulphide 
oxidoreductase family protein enables GO:0010181 FMN binding 
A2EVX8 TVAG_049830 
Pyridine nucleotide-disulphide 
oxidoreductase family protein involved_in GO:0055114 oxidation-reduction process 
A2EVX8 TVAG_049830 
Pyridine nucleotide-disulphide 
oxidoreductase family protein enables GO:0016491 oxidoreductase activity 
A2EXK6 TVAG_260830 Uncharacterized protein involved_in GO:0006511 ubiquitin-dependent protein catabolic process 
A2EXK6 TVAG_260830 Uncharacterized protein involved_in GO:0016567 protein ubiquitination 
A2EXK6 TVAG_260830 Uncharacterized protein involved_in GO:0042981 regulation of apoptotic process 
A2EZW3 TVAG_273370 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016791 phosphatase activity 
A2EZW3 TVAG_273370 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2EZW3 TVAG_273370 
Haloacid dehalogenase-like 
hydrolase family protein enables GO:0016787 hydrolase activity 
A2EZW3 TVAG_273370 
Haloacid dehalogenase-like 
hydrolase family protein involved_in GO:0016311 dephosphorylation 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating part_of GO:0005829 cytosol 
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A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0009051 pentose-phosphate shunt, oxidative branch 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0046177 D-gluconate catabolic process 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0050661 NADP binding 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0004616 phosphogluconate dehydrogenase (decarboxylating) activity 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0006098 pentose-phosphate shunt 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0050661 NADP binding 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0055114 oxidation-reduction process 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0004616 phosphogluconate dehydrogenase (decarboxylating) activity 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0016491 oxidoreductase activity 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0055114 oxidation-reduction process 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0006098 pentose-phosphate shunt 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0019521 D-gluconate metabolic process 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0016491 oxidoreductase activity 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating enables GO:0004616 phosphogluconate dehydrogenase (decarboxylating) activity 
A2EZW4 TVAG_273380 
6-phosphogluconate 
dehydrogenase, 
decarboxylating involved_in GO:0006098 pentose-phosphate shunt 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase involved_in GO:0055114 oxidation-reduction process 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0050660 flavin adenine dinucleotide binding 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase part_of GO:0045252 oxoglutarate dehydrogenase complex 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase part_of GO:0005739 mitochondrion 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0004148 dihydrolipoyl dehydrogenase activity 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0016668 
oxidoreductase activity, acting on a sulfur group of donors, NAD(P) 
as acceptor 
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A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0050660 flavin adenine dinucleotide binding 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase involved_in GO:0055114 oxidation-reduction process 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0004148 dihydrolipoyl dehydrogenase activity 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0016491 oxidoreductase activity 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase involved_in GO:0045454 cell redox homeostasis 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase involved_in GO:0055114 oxidation-reduction process 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0000166 nucleotide binding 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0016491 oxidoreductase activity 
A2F0F6 TVAG_272760 Dihydrolipoyl dehydrogenase enables GO:0004148 dihydrolipoyl dehydrogenase activity 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative enables GO:0004617 phosphoglycerate dehydrogenase activity 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative involved_in GO:0006520 cellular amino acid metabolic process 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative involved_in GO:0055114 oxidation-reduction process 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative enables GO:0016616 
oxidoreductase activity, acting on the CH-OH group of donors, NAD 
or NADP as acceptor 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative enables GO:0051287 NAD binding 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative involved_in GO:0055114 oxidation-reduction process 
A2F266 TVAG_154750 
D-isomer specific 2-
hydroxyacid dehydrogenase, 
putative enables GO:0016491 oxidoreductase activity 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase involved_in GO:0006511 ubiquitin-dependent protein catabolic process 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0008270 zinc ion binding 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase involved_in GO:0016579 protein deubiquitination 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0036459 thiol-dependent ubiquitinyl hydrolase activity 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0016787 hydrolase activity 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase involved_in GO:0006508 proteolysis 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0046872 metal ion binding 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0008233 peptidase activity 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0008234 cysteine-type peptidase activity 
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A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase enables GO:0036459 thiol-dependent ubiquitinyl hydrolase activity 
A2F507 TVAG_029150 
Ubiquitin carboxyl-terminal 
hydrolase involved_in GO:0016579 protein deubiquitination 
A2F9L1 TVAG_125360 Thioredoxin reductase enables GO:0004791 thioredoxin-disulfide reductase activity 
A2F9L1 TVAG_125360 Thioredoxin reductase involved_in GO:0019430 removal of superoxide radicals 
A2F9L1 TVAG_125360 Thioredoxin reductase involved_in GO:0055114 oxidation-reduction process 
A2F9L1 TVAG_125360 Thioredoxin reductase part_of GO:0005737 cytoplasm 
A2F9L1 TVAG_125360 Thioredoxin reductase enables GO:0016491 oxidoreductase activity 
A2F9L1 TVAG_125360 Thioredoxin reductase involved_in GO:0055114 oxidation-reduction process 
A2F9L1 TVAG_125360 Thioredoxin reductase enables GO:0016491 oxidoreductase activity 
A2F9L1 TVAG_125360 Thioredoxin reductase enables GO:0004791 thioredoxin-disulfide reductase activity 
A2F9L1 TVAG_125360 Thioredoxin reductase involved_in GO:0019430 removal of superoxide radicals 
A2F9L1 TVAG_125360 Thioredoxin reductase enables GO:0004791 thioredoxin-disulfide reductase activity 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative enables GO:0051539 4 iron, 4 sulfur cluster binding 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative enables GO:0005506 iron ion binding 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative involved_in GO:0055114 oxidation-reduction process 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative enables GO:0008901 ferredoxin hydrogenase activity 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative enables GO:0009055 electron transfer activity 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative enables GO:0051536 iron-sulfur cluster binding 
A2FCW4 TVAG_037570 
64kDa iron hydrogenase, 
putative involved_in GO:0022900 electron transport chain 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein involved_in GO:0035556 intracellular signal transduction 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein involved_in GO:0006468 protein phosphorylation 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein part_of GO:0005737 cytoplasm 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein part_of GO:0005634 nucleus 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein enables GO:0004674 protein serine/threonine kinase activity 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein enables GO:0004672 protein kinase activity 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein enables GO:0005524 ATP binding 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein involved_in GO:0006468 protein phosphorylation 
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A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein enables GO:0016301 kinase activity 
A2FDI8 TVAG_315190 
Protein kinase domain-
containing protein involved_in GO:0016310 phosphorylation 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0006007 glucose catabolic process 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0051289 protein homotetramerization 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0070095 fructose-6-phosphate binding 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0003872 6-phosphofructokinase activity 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0005524 ATP binding 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein part_of GO:0005945 6-phosphofructokinase complex 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0006002 fructose 6-phosphate metabolic process 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0016208 AMP binding 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0030388 fructose 1,6-bisphosphate metabolic process 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0042802 identical protein binding 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0048029 monosaccharide binding 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0061621 canonical glycolysis 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0003872 6-phosphofructokinase activity 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0005524 ATP binding 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0006002 fructose 6-phosphate metabolic process 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0006096 glycolytic process 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0008443 phosphofructokinase activity 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein enables GO:0016301 kinase activity 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0016310 phosphorylation 
A2FKA7 TVAG_293770 
PFK domain-containing 
protein involved_in GO:0046835 carbohydrate phosphorylation 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein involved_in GO:0006886 intracellular protein transport 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein involved_in GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport 
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A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein involved_in GO:0007029 endoplasmic reticulum organization 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein part_of GO:0030127 COPII vesicle coat 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein part_of GO:0070971 endoplasmic reticulum exit site 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein enables GO:0005198 structural molecule activity 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein involved_in GO:0090110 COPII-coated vesicle cargo loading 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein involved_in GO:0090114 COPII-coated vesicle budding 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein involved_in GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein part_of GO:0000139 Golgi membrane 
A2FLD2 TVAG_057830 
WD_REPEATS_REGION 
domain-containing protein part_of GO:0000139 Golgi membrane 
A2FRN2 TVAG_327610 
Cytidyltransferase-related 
domain containing protein involved_in GO:0009058 biosynthetic process 
A2FRN2 TVAG_327610 
Cytidyltransferase-related 
domain containing protein enables GO:0003824 catalytic activity 
A2FRN2 TVAG_327610 
Cytidyltransferase-related 
domain containing protein enables GO:0016740 transferase activity 
A2G214 TVAG_181540 
USP domain-containing 
protein enables GO:0004843 thiol-dependent ubiquitin-specific protease activity 
A2G214 TVAG_181540 
USP domain-containing 
protein part_of GO:0005829 cytosol 
A2G214 TVAG_181540 
USP domain-containing 
protein enables GO:0004197 cysteine-type endopeptidase activity 
A2G214 TVAG_181540 
USP domain-containing 
protein part_of GO:0005634 nucleus 
A2G214 TVAG_181540 
USP domain-containing 
protein involved_in GO:0016579 protein deubiquitination 
A2G214 TVAG_181540 
USP domain-containing 
protein involved_in GO:0006511 ubiquitin-dependent protein catabolic process 
A2G214 TVAG_181540 
USP domain-containing 
protein involved_in GO:0016579 protein deubiquitination 
A2G214 TVAG_181540 
USP domain-containing 
protein enables GO:0036459 thiol-dependent ubiquitinyl hydrolase activity 
A2G214 TVAG_181540 
USP domain-containing 
protein enables GO:0016787 hydrolase activity 
A2G4A3 TVAG_374870 
Doublecortin domain-
containing protein involved_in GO:0035556 intracellular signal transduction 
A2GEF2 TVAG_414560 
NAD(P)-bd_dom domain-
containing protein enables GO:0008460 dTDP-glucose 4,6-dehydratase activity 
A2GEF2 TVAG_414560 
NAD(P)-bd_dom domain-
containing protein involved_in GO:0009225 nucleotide-sugar metabolic process 
54 
 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein enables GO:0032051 clathrin light chain binding 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein part_of GO:0071439 clathrin complex 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein involved_in GO:0006898 receptor-mediated endocytosis 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein enables GO:0005198 structural molecule activity 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein involved_in GO:0016192 vesicle-mediated transport 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein involved_in GO:0006886 intracellular protein transport 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein part_of GO:0030130 clathrin coat of trans-Golgi network vesicle 
A2GLT5 TVAG_562550 
Clathrin heavy chain-related 
protein part_of GO:0030132 clathrin coat of coated pit 
  
Supplementary Table 2- 1. Available QuickGO analysis of target proteins 
Of the 61 proteins found, only 50 had any GO annotation. All annotations are provided in the 
table. Where GO annotations were unified, the principal annotation was also used in Table 2-1 
and subsequently in construction of the pie chart in Figure 2-3A.  
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Accession Functional Group TIGR Description 
Contains 
import 
motif? 
Class in 
training 
set 
 final 
MOT+ 
score  
final 
MOT+ 
rank 
 final 
MOT- 
score  
final 
MOT- 
rank 
TVAG_272760 Amino Acid Metabolism 
dihydrolipoamide dehydrogenase family 
protein no 
 
0.4350 1899 0.9999 46 
TVAG_100550 Amino Acid Metabolism Glycine cleavage H-protein no 
 
0.9996 97 0.9867 181 
TVAG_056190 Amino Acid Metabolism 
family M20, peptidase T-like 
metallopeptidase no 
 
0.3457 2186 0.9846 186 
TVAG_054490 Amino Acid Metabolism beta-eliminating lyase, putative no 
 
0.9993 123 0.9453 276 
TVAG_109540 Amino Acid Metabolism 
serine hydroxymethyltransferase family 
protein no 
 
0.8628 830 0.8307 414 
TVAG_098820 Amino Acid Metabolism 
aminotransferase, classes I and II family 
protein no 
 
0.0507 5093 0.3135 982 
TVAG_183300 Amino Acid Metabolism aminotransferase, class V family protein no 
 
0.0005 19880 0.3061 1000 
TVAG_074600 Amino Acid Metabolism 
aminotransferase, classes I and II family 
protein no 
 
0.1444 3369 0.2101 1220 
TVAG_025980 Amino Acid Metabolism glutamate dehydrogenase, putative no 
 
0.0373 5639 0.1533 1403 
TVAG_268020 Amino Acid Metabolism 
aminotransferase, classes I and II family 
protein no 
 
0.0573 4871 0.0736 1915 
TVAG_147790 Amino Acid Metabolism methionine gamma-lyase no 
 
0.0010 16653 0.0691 1999 
TVAG_088220 Amino Acid Metabolism 
aminotransferase, classes I and II family 
protein no 
 
0.0291 6143 0.0311 2781 
TVAG_177600 Amino Acid Metabolism Glycine cleavage H-protein no 
 
0.6079 1439 0.0222 3253 
TVAG_419720 Amino Acid Metabolism 
aminotransferase, classes I and II family 
protein no 
 
0.0410 5480 0.0217 3321 
TVAG_208470 Amino Acid Metabolism threonyl-tRNA synthetase family protein no 
 
0.0233 6610 0.0063 5597 
TVAG_547520 Amino Acid Metabolism cysteine synthases family protein no 
 
0.0079 9211 0.0061 5676 
TVAG_267950 Amino Acid Metabolism hypothetical protein no 
 
0.0001 31361 0.0056 5892 
TVAG_379550 Amino Acid Metabolism 
aminotransferase, classes I and II family 
protein yes 
 
0.8885 763 0.0018 9574 
TVAG_081640 Amino Acid Metabolism conserved hypothetical protein no 
 
0.9877 320 0.0005 14666 
TVAG_344520 Amino Acid Metabolism Amidinotransferase family protein no 
 
0.0000 33724 0.0005 15455 
TVAG_152430 Amino Acid Metabolism lysyl-tRNA synthetase family protein no 
 
0.0000 33999 0.0001 26838 
TVAG_183850 Amino Acid Metabolism Amidinotransferase family protein no 
 
0.0079 9205 0.0000 54681 
TVAG_479760 ATPases hypothetical protein no 
 
0.0000 46486 0.0002 22297 
TVAG_075320 ATPases 
V-type ATPase 116kDa subunit family 
protein no 
 
0.0697 4500 0.0001 29584 
TVAG_277590 ATPases calcium-translocating P-type ATPase no 
 
0.0046 10923 0.0000 31044 
TVAG_420260 ATPases hypothetical protein no 
 
0.0000 39288 0.0000 37299 
TVAG_262750 ATPases hypothetical protein no 
 
0.0008 17874 0.0000 42536 
TVAG_006020 ATPases hypothetical protein no 
 
0.0000 39375 0.0000 46589 
TVAG_178030 ATPases calcium-translocating P-type ATPase no 
 
0.0000 37639 0.0000 48758 
TVAG_324980 ATPases adenosinetriphosphatase, putative no 
 
0.0000 48392 0.0000 54617 
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TVAG_234160 Cytoskeletal Proteins actin related protein, putative no 
 
0.0122 8052 0.1149 1593 
TVAG_087140 Cytoskeletal Proteins 
Arp2/3 complex, 34kD subunit p34-Arc 
family no 
 
0.0096 8729 0.0008 12524 
TVAG_376130 Cytoskeletal Proteins actin-binding protein, putative no 
 
0.0353 5730 0.0008 12955 
TVAG_239310 Cytoskeletal Proteins actinin, putative no 
 
0.0035 11827 0.0003 17285 
TVAG_381030 Cytoskeletal Proteins hypothetical protein no 
 
0.0004 22089 0.0001 24413 
TVAG_351310 Cytoskeletal Proteins fimbrin, putative no 
 
0.0008 17967 0.0000 37951 
TVAG_190450 Cytoskeletal Proteins alpha-actinin, putative no 
 
0.0000 44256 0.0000 49232 
TVAG_354020 Cytoskeletal Proteins Actin family protein no 
 
0.0000 58953 0.0000 53074 
TVAG_192620 Cytoskeletal Proteins 
Cofilin/tropomyosin-type actin-binding 
protein no negative 0.0000 58876 0.0000 56645 
TVAG_008680 Cytoskeletal Proteins beta-tubulin, putative no negative 0.0000 59513 0.0000 59449 
TVAG_149090 Cytoskeletal Proteins actin no negative 0.0000 59575 0.0000 59505 
TVAG_292580 Cytosolic Chaperones 
peptidyl-prolyl cis-trans isomerase, FKBP-
type no 
 
0.1362 3468 0.5788 657 
TVAG_381290 Cytosolic Chaperones Hsp20/alpha crystallin family protein no 
 
0.6341 1378 0.1130 1603 
TVAG_182370 Cytosolic Chaperones chaperonin subunit eta CCTeta, putative no 
 
0.0231 6638 0.0464 2388 
TVAG_435000 Cytosolic Chaperones 
peptidyl-prolyl cis-trans isomerase, FKBP-
type no 
 
0.0002 25231 0.0063 5603 
TVAG_139320 Cytosolic Chaperones dnaK protein no 
 
0.0000 40637 0.0002 18933 
TVAG_153560 Cytosolic Chaperones heat shock protein, putative no 
 
0.0000 50328 0.0001 25001 
TVAG_277390 Cytosolic Chaperones cytosolic cyclophilin, putative no 
 
0.0001 29975 0.0000 30711 
TVAG_044510 Cytosolic Chaperones cytoplasmic heat shock protein 70, putative no 
 
0.0000 47545 0.0000 32547 
TVAG_267870 Energy Metabolism malate dehydrogenase:SUBUNIT=A yes 
 
1.0000 2 1.0000 1 
TVAG_340290 Energy Metabolism adhesin AP65-1 precursor yes positive 1.0000 4 1.0000 2 
TVAG_412220 Energy Metabolism malate dehydrogenase:SUBUNIT=A yes positive 1.0000 5 1.0000 3 
TVAG_183790 Energy Metabolism AP65-3 adhesin yes positive 1.0000 6 1.0000 5 
TVAG_416100 Energy Metabolism malate dehydrogenase:SUBUNIT=A yes positive 1.0000 9 1.0000 7 
TVAG_068130 Energy Metabolism malate dehydrogenase:SUBUNIT=A no positive 1.0000 23 1.0000 8 
TVAG_238830 Energy Metabolism malate dehydrogenase:SUBUNIT=B yes positive 1.0000 3 1.0000 9 
TVAG_144730 Energy Metabolism adhesin protein AP51-2, putative yes positive 1.0000 7 1.0000 21 
TVAG_296220 Energy Metabolism 
Respiratory-chain NADH dehydrogenase 24 
Kd yes positive 1.0000 20 1.0000 25 
TVAG_047890 Energy Metabolism hypothetical protein yes positive 1.0000 13 1.0000 27 
TVAG_259190 Energy Metabolism 
Succinyl-CoA ligase beta-chain, 
hydrogenosomal yes positive 1.0000 17 1.0000 29 
TVAG_318670 Energy Metabolism adhesin protein AP33-1 yes positive 1.0000 12 1.0000 30 
TVAG_165340 Energy Metabolism hypothetical protein yes positive 1.0000 11 0.9999 37 
TVAG_183500 Energy Metabolism adhesin protein AP51-3, putative yes positive 1.0000 18 0.9999 38 
TVAG_182620 Energy Metabolism TvhydB protein, putative no positive 1.0000 35 0.9999 41 
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TVAG_310050 Energy Metabolism TvhydB protein, putative no 
 
0.9856 346 0.9999 47 
TVAG_198110 Energy Metabolism pyruvate:ferredoxin oxidoreductase A yes positive 1.0000 24 0.9998 50 
TVAG_230580 Energy Metabolism pyruvate:ferredoxin oxidoreductase BI yes 
 
1.0000 19 0.9998 54 
TVAG_395550 Energy Metabolism hypothetical protein no positive 1.0000 28 0.9997 59 
TVAG_254890 Energy Metabolism pyruvate:ferredoxin oxidoreductase E yes 
 
1.0000 34 0.9995 70 
TVAG_242960 Energy Metabolism pyruvate:ferredoxin oxidoreductase BII yes 
 
1.0000 51 0.9959 116 
TVAG_113870 Energy Metabolism hypothetical protein no 
 
0.9998 86 0.9837 188 
TVAG_489800 Energy Metabolism adenylate kinase yes positive 1.0000 32 0.9815 192 
TVAG_328940 Energy Metabolism alcohol dehydrogenase, iron-containing no 
 
0.2360 2711 0.9502 266 
TVAG_466790 Energy Metabolism pyruvate:ferredoxin oxidoreductase F no 
 
0.9971 193 0.9387 287 
TVAG_133030 Energy Metabolism hydrogenase chain, putative yes 
 
0.9895 307 0.9319 300 
TVAG_164890 Energy Metabolism hypothetical protein no 
 
0.9911 291 0.9034 343 
TVAG_105770 Energy Metabolism pyruvate:ferredoxin oxidoreductase C no 
 
0.9326 615 0.8792 367 
TVAG_228780 Energy Metabolism alcohol dehydrogenase 1, putative no 
 
0.7502 1113 0.7622 479 
TVAG_003900 Energy Metabolism Ferredoxin 1 yes 
 
0.0953 3998 0.6835 547 
TVAG_399860 Energy Metabolism Ferredoxin 2 yes 
 
0.0124 8015 0.0630 2110 
TVAG_361590 Energy Metabolism 64kDa iron hydrogenase, putative yes 
 
0.9980 164 0.0155 3852 
TVAG_292710 Energy Metabolism Ferredoxin 4 no 
 
0.5173 1639 0.0125 4231 
TVAG_037570 Energy Metabolism 64kDa iron hydrogenase, putative yes 
 
0.4551 1806 0.0091 4819 
TVAG_327470 Energy Metabolism alcohol dehydrogenase no 
 
0.9803 397 0.0081 5042 
TVAG_160930 Energy Metabolism 
Iron only hydrogenase large subunit, C-
terminal yes 
 
0.4645 1768 0.0006 14196 
TVAG_255980 Energy Metabolism hypothetical protein yes 
 
0.4476 1825 0.0001 27557 
TVAG_091590 ER hypothetical protein no 
 
0.0001 29004 0.0182 3553 
TVAG_150170 ER ORMDL family protein no 
 
0.0107 8390 0.0034 7490 
TVAG_318870 ER spermatogenesis associated factor, putative no 
 
0.0001 32534 0.0026 8292 
TVAG_092490 ER 
endoplasmic reticulum heat shock protein 
70, put. no 
 
0.0000 46669 0.0007 13419 
TVAG_379250 ER conserved hypothetical protein no 
 
0.2793 2494 0.0001 27521 
TVAG_039020 ER conserved hypothetical protein no 
 
0.0000 42846 0.0000 42943 
TVAG_361540 
Fe-S Cluster Assembly 
Proteins HesB-like domain containing protein yes positive 1.0000 14 1.0000 10 
TVAG_456770 
Fe-S Cluster Assembly 
Proteins HesB-like domain containing protein yes positive 1.0000 15 1.0000 11 
TVAG_257780 
Fe-S Cluster Assembly 
Proteins Fe-hydrogenase assembly protein, putative no positive 1.0000 10 1.0000 14 
TVAG_432650 
Fe-S Cluster Assembly 
Proteins NifU-like protein, putative no 
 
0.3337 2248 0.9921 143 
TVAG_239660 
Fe-S Cluster Assembly 
Proteins IscS/NifS-like protein no 
 
0.0017 14522 0.6351 590 
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TVAG_422630 
Fe-S Cluster Assembly 
Proteins co-chaperone Hsc20 family protein no 
 
0.1543 3287 0.1466 1430 
TVAG_032090 
Fe-S Cluster Assembly 
Proteins co-chaperone Hsc20 family protein no 
 
0.5431 1584 0.1081 1623 
TVAG_342900 Flavin Proteins Isoflavone reductase, putative no 
 
0.6110 1429 0.9487 269 
TVAG_152690 Flavin Proteins 
oxidoreductase, FAD/FMN-binding family 
protein no 
 
0.9978 174 0.9013 345 
TVAG_040030 Flavin Proteins conserved hypothetical protein yes 
 
0.9710 460 0.6777 554 
TVAG_036010 Flavin Proteins Hydrogenosomal oxygen reductase yes 
 
0.9999 60 0.4543 777 
TVAG_154730 Flavin Proteins iron-sulfur flavoprotein, putative yes 
 
0.9987 152 0.2227 1190 
TVAG_127520 Flavin Proteins NADH:flavin oxidoreductase no 
 
0.8768 800 0.0808 1825 
TVAG_356810 Flavin Proteins nitroimidazole resistance protein, putative yes 
 
0.4459 1875 0.0787 1843 
TVAG_327760 Flavin Proteins iron-sulfur flavoprotein, putative no 
 
0.0483 5178 0.0235 3166 
TVAG_351540 Flavin Proteins 
oxidoreductase, FAD/FMN-binding family 
protein no 
 
0.0010 16813 0.0080 5073 
TVAG_049830 Flavin Proteins 
Pyridine nucleotide-disulphide 
oxidoreductase family protein no 
 
0.0087 8944 0.0049 6246 
TVAG_265760 Flavin Proteins 
oxidoreductase, FAD/FMN-binding family 
protein no 
 
0.0369 5655 0.0003 17884 
TVAG_445730 
Hydrogenosomal 
Chaperones chaperonin, 10 kDa family protein yes 
 
0.9995 112 1.0000 28 
TVAG_392320 
Hydrogenosomal 
Chaperones chaperonin, 10 kDa family protein yes 
 
0.9912 288 0.9999 44 
TVAG_088050 
Hydrogenosomal 
Chaperones chaperonin 60, putative yes positive 1.0000 29 0.9691 234 
TVAG_297650 
Hydrogenosomal 
Chaperones co-chaperone GrpE family protein yes 
 
0.6775 1284 0.8099 441 
TVAG_191660 
Hydrogenosomal 
Chaperones hypothetical protein yes 
 
0.4248 1930 0.6093 616 
TVAG_041340 
Hydrogenosomal 
Chaperones chaperonin, 10 kDa family protein yes 
 
0.9999 65 0.3019 1007 
TVAG_203620 
Hydrogenosomal 
Chaperones chaperonin 60, putative yes 
 
0.9999 75 0.2146 1207 
TVAG_167250 
Hydrogenosomal 
Chaperones chaperonin, putative yes 
 
0.9851 356 0.0027 8226 
TVAG_340390 
Hydrogenosomal 
Chaperones mitochondrial-type HSP70, putative yes 
 
0.0461 5252 0.0019 9525 
TVAG_019190 
Hydrogenosomal 
Chaperones DnaJ domain containing protein yes 
 
0.8964 737 0.0006 14138 
TVAG_237140 
Hydrogenosomal 
Chaperones mitochondrial-type HSP70, putative yes 
 
0.0166 7338 0.0000 32834 
TVAG_433130 
Hydrogenosomal 
Chaperones Heat shock 70 kDa protein, putative yes 
 
0.0052 10459 0.0000 42800 
TVAG_498620 Hypothetical proteins hypothetical protein no 
 
0.0002 24650 0.7158 515 
TVAG_057110 Hypothetical proteins methylesterase-like serine peptidase no 
 
0.1443 3372 0.3461 915 
TVAG_423530 Hypothetical proteins hypothetical protein no 
 
0.0358 5712 0.0576 2183 
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TVAG_277930 Hypothetical proteins hypothetical protein no 
 
0.0081 9171 0.0496 2332 
TVAG_077910 Hypothetical proteins hypothetical protein no 
 
0.0816 4208 0.0438 2437 
TVAG_440200 Hypothetical proteins hypothetical protein no 
 
0.1769 3078 0.0253 3031 
TVAG_455090 Hypothetical proteins hypothetical protein no 
 
0.0215 6799 0.0252 3045 
TVAG_146920 Hypothetical proteins hypothetical protein no 
 
0.5271 1620 0.0092 4810 
TVAG_377380 Hypothetical proteins hypothetical protein no 
 
0.0109 8351 0.0091 4825 
TVAG_425470 Hypothetical proteins hypothetical protein no 
 
0.0032 12126 0.0087 4918 
TVAG_177910 Hypothetical proteins hypothetical protein no 
 
0.0012 15824 0.0058 5830 
TVAG_311860 Hypothetical proteins hypothetical protein no 
 
0.0001 30137 0.0052 6107 
TVAG_284380 Hypothetical proteins hypothetical protein no 
 
0.0000 52998 0.0042 6834 
TVAG_332970 Hypothetical proteins hypothetical protein no 
 
0.0001 29639 0.0042 6847 
TVAG_468220 Hypothetical proteins conserved hypothetical protein no 
 
0.3944 2035 0.0038 7204 
TVAG_393390 Hypothetical proteins hypothetical protein no 
 
0.0034 11951 0.0029 8057 
TVAG_198090 Hypothetical proteins hypothetical protein no 
 
0.8419 879 0.0028 8123 
TVAG_026100 Hypothetical proteins hypothetical protein no 
 
0.0231 6633 0.0021 8882 
TVAG_115470 Hypothetical proteins hypothetical protein no 
 
0.0044 11025 0.0019 9415 
TVAG_123850 Hypothetical proteins hypothetical protein no 
 
0.0179 7151 0.0014 10498 
TVAG_237550 Hypothetical proteins hypothetical protein no 
 
0.0405 5501 0.0009 12028 
TVAG_117090 Hypothetical proteins hypothetical protein no 
 
0.0000 41586 0.0009 12238 
TVAG_028050 Hypothetical proteins hypothetical protein no 
 
0.0218 6783 0.0008 12376 
TVAG_437350 Hypothetical proteins hypothetical protein no 
 
0.0001 27118 0.0008 12641 
TVAG_264120 Hypothetical proteins hypothetical protein no 
 
0.0002 24038 0.0008 12954 
TVAG_137270 Hypothetical proteins hypothetical protein no 
 
0.0000 45226 0.0007 13756 
TVAG_416710 Hypothetical proteins hypothetical protein no 
 
0.0001 29848 0.0006 14127 
TVAG_038870 Hypothetical proteins hypothetical protein no 
 
0.0367 5665 0.0005 14905 
TVAG_399830 Hypothetical proteins hypothetical protein no 
 
0.0000 40367 0.0005 15388 
TVAG_234150 Hypothetical proteins FHA domain containing protein no 
 
0.0001 29109 0.0005 15490 
TVAG_122960 Hypothetical proteins hypothetical protein no 
 
0.0011 16256 0.0004 15621 
TVAG_067030 Hypothetical proteins hypothetical protein no 
 
0.0002 24609 0.0004 16109 
TVAG_167240 Hypothetical proteins hypothetical protein no 
 
0.0907 4060 0.0004 16209 
TVAG_209310 Hypothetical proteins hypothetical protein no 
 
0.0000 54929 0.0004 16942 
TVAG_056920 Hypothetical proteins hypothetical protein no 
 
0.0013 15586 0.0003 17311 
TVAG_001130 Hypothetical proteins hypothetical protein no 
 
0.0000 45405 0.0003 17756 
TVAG_139550 Hypothetical proteins hypothetical protein no 
 
0.0000 49791 0.0003 18384 
TVAG_260830 Hypothetical proteins hypothetical protein no 
 
0.0020 14013 0.0002 19847 
TVAG_447580 Hypothetical proteins hypothetical protein no 
 
0.0001 32843 0.0002 19855 
TVAG_416700 Hypothetical proteins hypothetical protein no 
 
0.0043 11080 0.0002 19905 
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TVAG_369980 Hypothetical proteins hypothetical protein no 
 
0.0000 48231 0.0002 20807 
TVAG_337970 Hypothetical proteins hypothetical protein no 
 
0.0433 5380 0.0002 21535 
TVAG_185900 Hypothetical proteins hypothetical protein no 
 
0.0000 39122 0.0002 21562 
TVAG_195900 Hypothetical proteins hypothetical protein no 
 
0.0001 31541 0.0002 21608 
TVAG_217400 Hypothetical proteins hypothetical protein no 
 
0.0000 51074 0.0002 22291 
TVAG_249920 Hypothetical proteins hypothetical protein no 
 
0.0009 17273 0.0001 22696 
TVAG_174010 Hypothetical proteins hypothetical protein no 
 
0.0001 31979 0.0001 23047 
TVAG_539120 Hypothetical proteins hypothetical protein no 
 
0.0000 36646 0.0001 23089 
TVAG_132350 Hypothetical proteins conserved hypothetical protein no 
 
0.0004 22085 0.0001 23167 
TVAG_197670 Hypothetical proteins hypothetical protein no 
 
0.0000 44838 0.0001 23304 
TVAG_136450 Hypothetical proteins hypothetical protein no 
 
0.1672 3167 0.0001 23516 
TVAG_263350 Hypothetical proteins conserved hypothetical protein no 
 
0.0019 14144 0.0001 23910 
TVAG_226310 Hypothetical proteins hypothetical protein no 
 
0.0032 12108 0.0001 24948 
TVAG_342980 Hypothetical proteins hypothetical protein no 
 
0.0058 10162 0.0001 26258 
TVAG_493810 Hypothetical proteins hypothetical protein no 
 
0.0015 14966 0.0001 26332 
TVAG_185520 Hypothetical proteins hypothetical protein no 
 
0.0001 30871 0.0001 26411 
TVAG_247370 Hypothetical proteins hypothetical protein no 
 
0.0003 23249 0.0001 26498 
TVAG_495570 Hypothetical proteins hypothetical protein no 
 
0.1265 3554 0.0001 26887 
TVAG_083420 Hypothetical proteins hypothetical protein no 
 
0.0001 27980 0.0001 27466 
TVAG_450060 Hypothetical proteins hypothetical protein no 
 
0.0003 23560 0.0001 27674 
TVAG_046430 Hypothetical proteins conserved hypothetical protein no 
 
0.0732 4414 0.0001 27879 
TVAG_102740 Hypothetical proteins hypothetical protein no 
 
0.0000 37391 0.0001 27988 
TVAG_130330 Hypothetical proteins hypothetical protein no 
 
0.0000 47886 0.0001 28678 
TVAG_450220 Hypothetical proteins hypothetical protein no 
 
0.0074 9403 0.0000 29850 
TVAG_411140 Hypothetical proteins hypothetical protein no 
 
0.0033 12106 0.0000 29865 
TVAG_137750 Hypothetical proteins hypothetical protein no 
 
0.0519 5053 0.0000 29907 
TVAG_113880 Hypothetical proteins hypothetical protein no 
 
0.0000 36420 0.0000 30362 
TVAG_458060 Hypothetical proteins hypothetical protein no 
 
0.0000 33406 0.0000 30785 
TVAG_341190 Hypothetical proteins hypothetical protein no 
 
0.0004 21415 0.0000 31565 
TVAG_412480 Hypothetical proteins hypothetical protein no 
 
0.0474 5201 0.0000 32251 
TVAG_233680 Hypothetical proteins hypothetical protein no 
 
0.0000 37409 0.0000 32758 
TVAG_432870 Hypothetical proteins hypothetical protein no 
 
0.0210 6863 0.0000 34699 
TVAG_335500 Hypothetical proteins hypothetical protein no 
 
0.0000 42484 0.0000 35512 
TVAG_022530 Hypothetical proteins hypothetical protein no 
 
0.0009 17550 0.0000 35898 
TVAG_343040 Hypothetical proteins hypothetical protein no 
 
0.0000 35910 0.0000 36736 
TVAG_211970 Hypothetical proteins hypothetical protein no 
 
0.0000 40825 0.0000 37312 
TVAG_477200 Hypothetical proteins hypothetical protein no 
 
0.0000 52830 0.0000 38673 
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TVAG_392650 Hypothetical proteins hypothetical protein no 
 
0.0001 31852 0.0000 38770 
TVAG_283120 Hypothetical proteins hypothetical protein no 
 
0.0024 13283 0.0000 38840 
TVAG_106710 Hypothetical proteins hypothetical protein no 
 
0.0001 29709 0.0000 39496 
TVAG_044000 Hypothetical proteins hypothetical protein no 
 
0.1220 3598 0.0000 39930 
TVAG_011550 Hypothetical proteins hypothetical protein no 
 
0.0000 40968 0.0000 40371 
TVAG_137760 Hypothetical proteins hypothetical protein no 
 
0.0005 20491 0.0000 41338 
TVAG_340380 Hypothetical proteins hypothetical protein no 
 
0.0000 37602 0.0000 42651 
TVAG_399510 Hypothetical proteins hypothetical protein no 
 
0.0004 22038 0.0000 42679 
TVAG_302380 Hypothetical proteins hypothetical protein no 
 
0.0026 12892 0.0000 43745 
TVAG_442170 Hypothetical proteins hypothetical protein no 
 
0.0002 24093 0.0000 45156 
TVAG_530140 Hypothetical proteins hypothetical protein no 
 
0.0002 24245 0.0000 45280 
TVAG_420200 Hypothetical proteins hypothetical protein no 
 
0.0001 28224 0.0000 45339 
TVAG_468600 Hypothetical proteins hypothetical protein no 
 
0.0000 57076 0.0000 45843 
TVAG_165270 Hypothetical proteins hypothetical protein no 
 
0.0000 51885 0.0000 46202 
TVAG_343980 Hypothetical proteins hypothetical protein no 
 
0.0001 31593 0.0000 46546 
TVAG_371800 Hypothetical proteins hypothetical protein no 
 
0.0000 39529 0.0000 46807 
TVAG_140620 Hypothetical proteins hypothetical protein no 
 
0.0001 27977 0.0000 46843 
TVAG_053070 Hypothetical proteins hypothetical protein no 
 
0.0001 29489 0.0000 47140 
TVAG_214300 Hypothetical proteins hypothetical protein no 
 
0.0001 27759 0.0000 47164 
TVAG_192370 Hypothetical proteins hypothetical protein no 
 
0.0001 30811 0.0000 49146 
TVAG_038850 Hypothetical proteins hypothetical protein no 
 
0.0001 29759 0.0000 49736 
TVAG_213670 Hypothetical proteins hypothetical protein yes 
 
0.0556 4927 0.0000 50559 
TVAG_006090 Hypothetical proteins hypothetical protein no 
 
0.0004 22115 0.0000 53115 
TVAG_272350 Hypothetical proteins hypothetical protein no 
 
0.0000 41080 0.0000 53465 
TVAG_281980 Hypothetical proteins hypothetical protein no 
 
0.0000 58058 0.0000 53798 
TVAG_271850 Hypothetical proteins cec-1, putative no 
 
0.0000 33748 0.0000 55143 
TVAG_238370 Hypothetical proteins viral A-type inclusion protein, putative no 
 
0.0000 57670 0.0000 56372 
TVAG_506640 Hypothetical proteins conserved hypothetical protein no 
 
0.0000 53685 0.0000 57720 
TVAG_167810 Hypothetical proteins hypothetical protein no 
 
0.0000 39386 0.0000 58081 
TVAG_019960 Hypothetical proteins hypothetical protein no 
 
0.0000 57961 0.0000 58312 
TVAG_298320 Hypothetical proteins hypothetical protein no 
 
0.0000 52810 0.0000 58632 
TVAG_187360 Hypothetical proteins hypothetical protein no 
 
0.0000 59000 0.0000 59343 
TVAG_043470 Nuclear Protein hypothetical protein no 
 
0.0329 5886 0.0015 10221 
TVAG_271570 Nuclear Protein Nucleoside transporter family protein no 
 
0.0009 17391 0.0002 19734 
TVAG_332540 Nuclear Protein hypothetical protein no 
 
0.0000 49899 0.0000 46389 
TVAG_158990 Nuclear Protein RNA-binding protein, putative no negative 0.0000 53294 0.0000 46617 
TVAG_026390 Nuclear Protein Histone H2B, putative no negative 0.0000 59617 0.0000 59541 
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TVAG_021440 Nuclear Protein Histone H2A-IV, putative no negative 0.0000 59660 0.0000 59620 
TVAG_014920 Nuclear Protein histone H4-3 no negative 0.0000 59646 0.0000 59646 
TVAG_270750 Other function acetyltransferase, GNAT family protein no 
 
0.9958 220 0.9994 71 
TVAG_321030 Other function CoA binding domain containing protein yes 
 
1.0000 48 0.9706 230 
TVAG_293370 Other function 
Nucleoside diphosphate kinase family 
protein no 
 
0.9050 702 0.9475 272 
TVAG_454490 Other function purine nucleoside phosphorylase, putative no 
 
0.9992 132 0.7752 471 
TVAG_256720 Other function 
4-carboxymuconolactone decarboxylase 
family no 
 
0.8525 853 0.6234 604 
TVAG_321010 Other function AMP-binding enzyme family protein no 
 
0.9001 720 0.5644 676 
TVAG_107080 Other function 
4-carboxymuconolactone decarboxylase, 
putative no 
 
0.8299 918 0.1322 1486 
TVAG_065750 Other function Major Facilitator Superfamily protein no 
 
0.1264 3555 0.1216 1542 
TVAG_076230 Other function mrp, putative yes 
 
0.3040 2369 0.1178 1575 
TVAG_047210 Other function 
D-isomer 2-hydroxyacid dehydrogenase, 
put. yes 
 
0.8003 1003 0.0485 2343 
TVAG_139300 Other function 
phosphoenol pyruvate carboxykinase, 
putative no 
 
0.9433 578 0.0426 2454 
TVAG_388650 Other function 
aminotransferase, classes I and II family 
protein no 
 
0.0425 5414 0.0183 3532 
TVAG_325080 Other function metallo-beta-lactamase superfamily protein no 
 
0.1434 3390 0.0171 3635 
TVAG_310250 Other function 
phosphoenol pyruvate carboxykinase, 
putative no 
 
0.7289 1165 0.0114 4374 
TVAG_225930 Other function conserved hypothetical protein no 
 
0.9451 574 0.0093 4797 
TVAG_277050 Other function citrate lyase beta like, putative no 
 
0.0001 27618 0.0088 4894 
TVAG_217870 Other function mrp protein, putative yes 
 
0.3366 2236 0.0081 5043 
TVAG_038530 Other function carbamoyl transferase Z4209 , putative no 
 
0.6606 1313 0.0061 5651 
TVAG_424580 Other function mevalonate kinase family protein no 
 
0.0027 12760 0.0043 6815 
TVAG_083440 Other function conserved hypothetical protein no 
 
0.0000 34935 0.0023 8626 
TVAG_461020 Other function ABC transporter family protein no 
 
0.2462 2641 0.0013 10665 
TVAG_180400 Other function 
Endonuclease/Exonuclease/phosphatase 
family no 
 
0.0004 21957 0.0012 10983 
TVAG_118780 Other function EF hand family protein no 
 
0.3669 2117 0.0009 12148 
TVAG_346230 Other function haloacid dehalogenase-like hydrolase family no 
 
0.0150 7581 0.0006 13920 
TVAG_060450 Other function acetyltransferase, GNAT family protein no 
 
0.0033 12105 0.0005 15136 
TVAG_351320 Other function purine nucleoside phosphorylase, putative no 
 
0.0000 40573 0.0005 15264 
TVAG_076510 Other function serine palmitoyl transferase subunit, putative no 
 
0.0136 7796 0.0003 18316 
TVAG_256470 Other function 
Thiamin pyrophosphokinase, catalytic 
domain no 
 
0.0000 34447 0.0000 29690 
TVAG_386000 Other function TB2/DP1, HVA22 family protein no 
 
0.0000 55334 0.0000 35650 
TVAG_198430 Other function 14-3-3 protein no 
 
0.0001 32343 0.0000 41653 
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TVAG_049690 Other function 
Thiamin pyrophosphokinase, catalytic 
domain no 
 
0.0153 7539 0.0000 41765 
TVAG_048135 Other function P270 surface immunogen-like no 
 
0.0020 13868 0.0000 44072 
TVAG_096630 Other function 
Thiamin pyrophosphokinase, catalytic 
domain no 
 
0.0002 24543 0.0000 44337 
TVAG_454570 Other function erythrocyte binding protein, putative no 
 
0.0000 49835 0.0000 44669 
TVAG_037530 Other function EF hand family protein no 
 
0.0002 26530 0.0000 48462 
TVAG_092170 Other function 
preprotein translocase, SecY subunit, 
putative no 
 
0.0000 40725 0.0000 54127 
TVAG_055200 Oxygen Stress Response thioredoxin peroxidase no positive 1.0000 30 1.0000 4 
TVAG_064490 Oxygen Stress Response rubrerythrin, putative no positive 1.0000 27 1.0000 20 
TVAG_336320 Oxygen Stress Response hydroxylamine reductase, putative no 
 
0.9941 243 0.9912 147 
TVAG_206500 Oxygen Stress Response hybrid-cluster protein, putative no 
 
0.9678 477 0.9156 323 
TVAG_410350 Oxygen Stress Response hypothetical protein no 
 
0.0125 7989 0.0069 5421 
TVAG_114310 Oxygen Stress Response thioredoxin peroxidase no 
 
0.6582 1319 0.0030 7943 
TVAG_049140 Oxygen Stress Response chloroplastic iron superoxide dismutase no 
 
0.8205 951 0.0021 9020 
TVAG_039980 Oxygen Stress Response iron superoxide dismutase, putative no 
 
0.1061 3799 0.0011 11297 
TVAG_385350 Oxygen Stress Response Thioredoxin family protein yes 
 
0.0034 12005 0.0010 11779 
TVAG_224980 Peptidases peptidase T-like metallopeptidase no 
 
0.8507 858 0.9944 127 
TVAG_386080 Peptidases aminopeptidase P-like metallopeptidase no 
 
0.0006 19246 0.0547 2230 
TVAG_233350 Peptidases insulinase-like metallopeptidase no 
 
0.0922 4040 0.0013 10676 
TVAG_119710 Peptidases insulinase-like metallopeptidase no 
 
0.2700 2528 0.0003 18477 
TVAG_082020 Peptidases hypothetical protein no 
 
0.0000 40353 0.0000 41664 
TVAG_190580 Peptidases aminopeptidase P-like metallopeptidase no 
 
0.0000 46443 0.0000 54544 
TVAG_371680 Proteasome Degradation PCI domain containing protein no 
 
0.0000 34083 0.0000 35975 
TVAG_184150 Proteome Degradation polyubiquitin, putative no 
 
0.0021 13685 0.1027 1652 
TVAG_112860 Proteome Degradation Ubiquitin family protein no 
 
0.0004 21013 0.0006 13903 
TVAG_237680 
Putative Translocase and 
Carrier Proteins 
hydrogenosomal membrane protein 31 
precursor no positive 0.9999 71 0.9881 171 
TVAG_104250 
Putative Translocase and 
Carrier Proteins hydrogenosomal membrane protein Hmp35 no positive 1.0000 52 0.8476 406 
TVAG_031860 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.0002 24097 0.0060 5763 
TVAG_198350 
Putative Translocase and 
Carrier Proteins Mitochondrial import Tim17 protein family no 
 
0.1041 3830 0.0015 10106 
TVAG_178100 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.1206 3611 0.0007 13290 
TVAG_196220 
Putative Translocase and 
Carrier Proteins Mitochondrial carrier protein no 
 
0.0006 19283 0.0002 20615 
TVAG_370860 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.0774 4324 0.0001 25597 
TVAG_164560 
Putative Translocase and 
Carrier Proteins Mitochondrial carrier protein no 
 
0.0001 32068 0.0001 29001 
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TVAG_216170 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.0007 18489 0.0000 31128 
TVAG_470110 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.0003 22487 0.0000 38510 
TVAG_008790 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.0000 35801 0.0000 46595 
TVAG_262210 
Putative Translocase and 
Carrier Proteins Mitochondrial carrier protein no 
 
0.0000 32982 0.0000 53333 
TVAG_051820 
Putative Translocase and 
Carrier Proteins Mitochondrial carrier protein no 
 
0.0000 40206 0.0000 53519 
TVAG_123100 
Putative Translocase and 
Carrier Proteins hypothetical protein no 
 
0.0000 33180 0.0000 55521 
TVAG_110140 
Ribosomal and 
Associated Proteins ubiquitin, putative no 
 
0.0009 17212 0.0744 1895 
TVAG_172530 
Ribosomal and 
Associated Proteins hypothetical protein no 
 
0.0307 6015 0.0617 2130 
TVAG_119970 
Ribosomal and 
Associated Proteins hypothetical protein no 
 
0.0941 4013 0.0030 7805 
TVAG_067400 
Ribosomal and 
Associated Proteins elongation factor 1 alpha, putative no 
 
0.0054 10355 0.0011 11365 
TVAG_283020 
Ribosomal and 
Associated Proteins 
translation initiation factor eIF-5A family 
protein no 
 
0.0001 28339 0.0001 23537 
TVAG_276410 
Ribosomal and 
Associated Proteins hypothetical protein no 
 
0.0000 48921 0.0001 24866 
TVAG_045340 
Ribosomal and 
Associated Proteins hypothetical protein no 
 
0.0005 20315 0.0000 30998 
TVAG_248450 
Ribosomal and 
Associated Proteins conserved hypothetical protein no 
 
0.0005 20890 0.0000 31512 
TVAG_047460 
Ribosomal and 
Associated Proteins Ribosomal S3Ae, putative no negative 0.0000 58839 0.0000 51457 
TVAG_061890 
Ribosomal and 
Associated Proteins ribosomal protein L18ae, putative no negative 0.0000 58334 0.0000 53011 
TVAG_054130 
Ribosomal and 
Associated Proteins 60S ribosomal protein L7-2, putative no negative 0.0000 59043 0.0000 54747 
TVAG_380910 
Ribosomal and 
Associated Proteins 
eukaryotic translation initiation factor, 
putative no negative 0.0000 59138 0.0000 54929 
TVAG_319220 
Ribosomal and 
Associated Proteins Ribosomal protein S24e, putative no negative 0.0000 58408 0.0000 56098 
TVAG_178000 
Ribosomal and 
Associated Proteins ribosomal protein L23, putative no negative 0.0000 58705 0.0000 57034 
TVAG_272970 
Ribosomal and 
Associated Proteins Ribosomal protein S24e, putative no 
 
0.0000 58747 0.0000 58431 
TVAG_098450 
Ribosomal and 
Associated Proteins 40S ribosomal protein S4-C, putative no negative 0.0000 59359 0.0000 58910 
TVAG_020040 
Ribosomal and 
Associated Proteins 40S ribosomal protein S16, putative no negative 0.0000 59461 0.0000 58946 
TVAG_005910 
Ribosomal and 
Associated Proteins ribosomal protein L8, putative no negative 0.0000 59289 0.0000 59013 
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TVAG_064640 
Ribosomal and 
Associated Proteins ribosomal protein L5 no negative 0.0000 59280 0.0000 59157 
TVAG_265950 
Ribosomal and 
Associated Proteins Ribosomal protein L32, putative no negative 0.0000 59338 0.0000 59207 
TVAG_142440 
Ribosomal and 
Associated Proteins hypothetical protein no negative 0.0000 59302 0.0000 59230 
TVAG_074610 
Ribosomal and 
Associated Proteins ribosomal protein, putative no negative 0.0000 59301 0.0000 59239 
TVAG_112230 
Ribosomal and 
Associated Proteins Ribosomal protein L13e, putative no negative 0.0000 59458 0.0000 59242 
TVAG_044560 
Ribosomal and 
Associated Proteins 60S ribosomal protein L11, putative no negative 0.0000 59400 0.0000 59263 
TVAG_066030 
Ribosomal and 
Associated Proteins hypothetical protein no negative 0.0000 59506 0.0000 59290 
TVAG_051160 
Ribosomal and 
Associated Proteins ribosomal protein L10, putative no negative 0.0000 59352 0.0000 59298 
TVAG_240050 
Ribosomal and 
Associated Proteins ribosomal protein, putative no negative 0.0000 59351 0.0000 59316 
TVAG_120180 
Ribosomal and 
Associated Proteins Plectin/S10 domain containing protein no negative 0.0000 59376 0.0000 59317 
TVAG_074480 
Ribosomal and 
Associated Proteins ribosomal protein L10a no negative 0.0000 59394 0.0000 59324 
TVAG_182520 
Ribosomal and 
Associated Proteins Ribosomal protein L13e, putative no negative 0.0000 59413 0.0000 59328 
TVAG_423320 
Ribosomal and 
Associated Proteins Ribosomal protein L13e, putative no negative 0.0000 59483 0.0000 59328 
TVAG_020480 
Ribosomal and 
Associated Proteins ribosomal protein S13p/S18e, putative no negative 0.0000 59454 0.0000 59334 
TVAG_121550 
Ribosomal and 
Associated Proteins hypothetical protein no negative 0.0000 59521 0.0000 59340 
TVAG_006250 
Ribosomal and 
Associated Proteins ribosomal protein S15a no negative 0.0000 59449 0.0000 59362 
TVAG_128790 
Ribosomal and 
Associated Proteins ribosomal protein, putative no negative 0.0000 59419 0.0000 59372 
TVAG_106800 
Ribosomal and 
Associated Proteins Ribosomal protein S3, putative no negative 0.0000 59460 0.0000 59383 
TVAG_083260 
Ribosomal and 
Associated Proteins ribosomal protein L22, putative no negative 0.0000 59370 0.0000 59384 
TVAG_101690 
Ribosomal and 
Associated Proteins Ribosomal protein L24e, putative no negative 0.0000 59294 0.0000 59390 
TVAG_348090 
Ribosomal and 
Associated Proteins Ribosomal S3Ae, putative no negative 0.0000 59345 0.0000 59397 
TVAG_152720 
Ribosomal and 
Associated Proteins 40S ribosomal protein S14, putative no negative 0.0000 59263 0.0000 59433 
TVAG_117480 
Ribosomal and 
Associated Proteins ribosomal protein S14 no negative 0.0000 59355 0.0000 59435 
TVAG_054500 
Ribosomal and 
Associated Proteins ribosomal protein L6, putative no negative 0.0000 59450 0.0000 59438 
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TVAG_121100 
Ribosomal and 
Associated Proteins 60S ribosomal protein L18, putative no negative 0.0000 59505 0.0000 59441 
TVAG_342830 
Ribosomal and 
Associated Proteins ribosomal protein S14, putative no negative 0.0000 59365 0.0000 59452 
TVAG_119330 
Ribosomal and 
Associated Proteins ribosomal protein L21e, putative no negative 0.0000 59392 0.0000 59457 
TVAG_370550 
Ribosomal and 
Associated Proteins Ribosomal protein S6e, putative no negative 0.0000 59444 0.0000 59466 
TVAG_014160 
Ribosomal and 
Associated Proteins 60S ribosomal protein L12, putative no 
 
0.0000 59520 0.0000 59468 
TVAG_482430 
Ribosomal and 
Associated Proteins 60S ribosomal protein L18, putative no negative 0.0000 59423 0.0000 59473 
TVAG_015800 
Ribosomal and 
Associated Proteins 60S ribosomal protein L23, putative no negative 0.0000 59308 0.0000 59477 
TVAG_299380 
Ribosomal and 
Associated Proteins ribosomal protein S14, putative no negative 0.0000 59241 0.0000 59485 
TVAG_148950 
Ribosomal and 
Associated Proteins 60S ribosomal protein L15-1, putative no negative 0.0000 59427 0.0000 59486 
TVAG_013060 
Ribosomal and 
Associated Proteins hypothetical protein no negative 0.0000 59503 0.0000 59489 
TVAG_040820 
Ribosomal and 
Associated Proteins 40S ribosomal protein S17-B, putative no negative 0.0000 59624 0.0000 59512 
TVAG_033590 
Ribosomal and 
Associated Proteins Ribosomal protein S6e, putative no negative 0.0000 59474 0.0000 59527 
TVAG_041350 
Ribosomal and 
Associated Proteins hypothetical protein no negative 0.0000 59426 0.0000 59529 
TVAG_094720 
Ribosomal and 
Associated Proteins Ribosomal protein L34e, putative no negative 0.0000 59403 0.0000 59545 
TVAG_006170 
Ribosomal and 
Associated Proteins 60S ribosomal protein L19-3, putative no negative 0.0000 59360 0.0000 59593 
TVAG_464120 
Ribosomal and 
Associated Proteins ribosomal protein S14, putative no negative 0.0000 59386 0.0000 59601 
TVAG_038050 
Ribosomal and 
Associated Proteins hypothetical protein no negative 0.0000 59499 0.0000 59622 
TVAG_071920 
Ribosomal and 
Associated Proteins 40S ribosomal protein S23, putative no negative 0.0000 59608 0.0000 59653 
TVAG_218150 Signaling 
Adenylate and Guanylate cyclase catalytic 
domain containing protein no 
 
0.9515 558 0.3595 899 
TVAG_169060 Signaling Cdc42 homolog, putative no 
 
0.0002 24797 0.0002 18840 
TVAG_026290 Signaling hypothetical protein no 
 
0.0005 19877 0.0001 22834 
TVAG_491610 Signaling protein kinase, putative no 
 
0.0003 23677 0.0001 27794 
TVAG_464010 Signaling Calreticulin family protein no 
 
0.0000 41264 0.0001 28973 
TVAG_204940 Signaling Calreticulin family protein no 
 
0.0000 50569 0.0000 48144 
TVAG_453070 
Small GTPases and 
Associated Proteins Ras-related protein R-Ras2, putative no 
 
0.0007 18158 0.1236 1528 
TVAG_134510 
Small GTPases and 
Associated Proteins 
guanine nucleotide regulatory protein, 
putative no 
 
0.0287 6163 0.0774 1853 
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TVAG_446980 
Small GTPases and 
Associated Proteins GTP-binding protein, putative no 
 
0.0049 10636 0.0764 1872 
TVAG_383350 
Small GTPases and 
Associated Proteins GTP-binding protein YPTM2, putative no 
 
0.7808 1049 0.0483 2348 
TVAG_047800 
Small GTPases and 
Associated Proteins 
Ras-like GTP-binding protein YPT1, 
putative no 
 
0.4044 1994 0.0206 3375 
TVAG_499340 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0031 12287 0.0124 4238 
TVAG_362470 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0002 25300 0.0050 6192 
TVAG_390750 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.2865 2442 0.0047 6454 
TVAG_220970 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0444 5335 0.0044 6747 
TVAG_415960 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0030 12475 0.0041 6859 
TVAG_395100 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0238 6557 0.0024 8533 
TVAG_106390 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 35954 0.0018 9647 
TVAG_121740 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0045 10957 0.0017 9813 
TVAG_393370 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0093 8808 0.0015 10196 
TVAG_185340 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0165 7349 0.0015 10241 
TVAG_070500 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0848 4167 0.0015 10253 
TVAG_056480 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0012 15816 0.0014 10366 
TVAG_056930 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 52441 0.0014 10394 
TVAG_484100 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0046 10892 0.0013 10748 
TVAG_150540 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0007 18227 0.0012 11080 
TVAG_126970 
Small GTPases and 
Associated Proteins GDP dissociation inhibitor family protein no 
 
0.0008 18093 0.0010 11652 
TVAG_128860 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0694 4508 0.0009 12217 
TVAG_379850 
Small GTPases and 
Associated Proteins GTP-binding protein YPTM1, putative no 
 
0.2422 2669 0.0007 13469 
TVAG_261280 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0110 8344 0.0007 13701 
TVAG_383530 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 27211 0.0006 14106 
TVAG_081590 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0427 5410 0.0006 14338 
68 
 
TVAG_136740 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.1249 3567 0.0006 14570 
TVAG_211200 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0013 15709 0.0005 15411 
TVAG_159810 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 30277 0.0004 15696 
TVAG_192440 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0160 7426 0.0004 15779 
TVAG_416520 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0002 25596 0.0004 16210 
TVAG_093060 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0000 34336 0.0003 17145 
TVAG_349870 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0574 4868 0.0003 17450 
TVAG_456910 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 41033 0.0003 17517 
TVAG_384490 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0869 4135 0.0003 17928 
TVAG_158270 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0002 25943 0.0002 21058 
TVAG_397350 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 28662 0.0002 21387 
TVAG_328110 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0019 14195 0.0002 21420 
TVAG_079570 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0837 4183 0.0002 21523 
TVAG_409800 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 31270 0.0002 21756 
TVAG_079630 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0011 16551 0.0002 22119 
TVAG_044270 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0011 16347 0.0002 22214 
TVAG_404940 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 27818 0.0002 22217 
TVAG_104710 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0005 20216 0.0001 22856 
TVAG_498380 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0249 6469 0.0001 23293 
TVAG_462370 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0209 6877 0.0001 23980 
TVAG_216900 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0000 44163 0.0001 24307 
TVAG_169740 
Small GTPases and 
Associated Proteins Ras-related protein Rab11C, putative no 
 
0.0000 53701 0.0001 24832 
TVAG_065320 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0014 15452 0.0001 25535 
TVAG_151010 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0062 9911 0.0001 26201 
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TVAG_124590 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0173 7245 0.0001 26427 
TVAG_124540 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0004 21323 0.0001 26686 
TVAG_139270 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0015 15079 0.0001 26818 
TVAG_320200 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0010 16979 0.0001 26827 
TVAG_329350 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0072 9481 0.0001 28365 
TVAG_241150 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0023 13431 0.0001 28536 
TVAG_051830 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0107 8395 0.0001 29096 
TVAG_377960 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0000 43178 0.0001 29113 
TVAG_190510 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0035 11899 0.0000 30826 
TVAG_379590 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0000 41085 0.0000 31036 
TVAG_076670 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 37333 0.0000 31136 
TVAG_048600 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 27458 0.0000 31516 
TVAG_018050 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0072 9480 0.0000 31540 
TVAG_282070 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0248 6487 0.0000 32133 
TVAG_402160 
Small GTPases and 
Associated Proteins RasGEF domain containing protein no 
 
0.0059 10104 0.0000 32826 
TVAG_371280 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0024 13226 0.0000 33570 
TVAG_249220 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0012 15838 0.0000 33619 
TVAG_122340 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0002 26223 0.0000 34152 
TVAG_430220 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 40656 0.0000 34627 
TVAG_112840 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0003 23031 0.0000 35469 
TVAG_178380 
Small GTPases and 
Associated Proteins XRP2, putative no 
 
0.0007 18546 0.0000 35594 
TVAG_459470 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0005 20763 0.0000 35737 
TVAG_446610 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 33398 0.0000 37363 
TVAG_194760 
Small GTPases and 
Associated Proteins Kelch motif family protein no 
 
0.0001 31151 0.0000 37579 
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TVAG_101260 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0000 34562 0.0000 37663 
TVAG_373310 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0061 9959 0.0000 37727 
TVAG_446990 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0109 8357 0.0000 38419 
TVAG_055550 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0002 24237 0.0000 38441 
TVAG_308190 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0019 14116 0.0000 39506 
TVAG_161280 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0023 13329 0.0000 39548 
TVAG_300910 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0037 11570 0.0000 39816 
TVAG_029020 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0027 12759 0.0000 40025 
TVAG_136260 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0011 16421 0.0000 40282 
TVAG_006260 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0005 20361 0.0000 40646 
TVAG_504530 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 28213 0.0000 40807 
TVAG_462450 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0002 26504 0.0000 41567 
TVAG_060820 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 41304 0.0000 41851 
TVAG_350580 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0001 27355 0.0000 42474 
TVAG_122270 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0032 12118 0.0000 42533 
TVAG_434770 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 34865 0.0000 42703 
TVAG_454230 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0003 22496 0.0000 43030 
TVAG_159730 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0600 4768 0.0000 43220 
TVAG_036230 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0797 4250 0.0000 43281 
TVAG_201980 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0953 3999 0.0000 43771 
TVAG_193770 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0132 7863 0.0000 44877 
TVAG_212310 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0007 18328 0.0000 45711 
TVAG_080400 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 42174 0.0000 46292 
TVAG_236570 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0510 5080 0.0000 47789 
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TVAG_024790 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0011 16359 0.0000 47873 
TVAG_090060 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0027 12850 0.0000 47997 
TVAG_320300 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0008 17816 0.0000 48424 
TVAG_257310 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0056 10221 0.0000 50133 
TVAG_364210 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0008 17965 0.0000 50169 
TVAG_283380 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0000 56334 0.0000 50618 
TVAG_422690 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 46008 0.0000 50722 
TVAG_527180 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 39292 0.0000 52460 
TVAG_038950 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0029 12530 0.0000 53112 
TVAG_180430 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 44009 0.0000 53240 
TVAG_405730 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0036 11696 0.0000 53507 
TVAG_181000 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0100 8599 0.0000 53756 
TVAG_424920 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0223 6729 0.0000 53834 
TVAG_391930 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0007 18443 0.0000 54018 
TVAG_440690 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 29509 0.0000 54531 
TVAG_015270 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0013 15738 0.0000 54548 
TVAG_348580 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 31190 0.0000 54646 
TVAG_092740 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 38062 0.0000 54827 
TVAG_020610 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0002 26435 0.0000 54847 
TVAG_157610 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0004 21760 0.0000 55094 
TVAG_038420 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0000 56806 0.0000 55227 
TVAG_278280 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 29583 0.0000 55230 
TVAG_008100 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0012 15793 0.0000 55250 
TVAG_101480 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 34318 0.0000 56225 
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TVAG_442270 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0004 21356 0.0000 56634 
TVAG_075460 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0117 8159 0.0000 56702 
TVAG_340860 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0000 35875 0.0000 56911 
TVAG_351500 
Small GTPases and 
Associated Proteins 
Ras-like GTP-binding protein RYL1, 
putative no 
 
0.0000 55787 0.0000 57053 
TVAG_147840 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 34349 0.0000 57112 
TVAG_297320 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0005 20308 0.0000 57589 
TVAG_074410 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0001 28148 0.0000 57623 
TVAG_331490 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0022 13618 0.0000 57715 
TVAG_006280 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0054 10340 0.0000 57859 
TVAG_185300 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0017 14573 0.0000 58084 
TVAG_085320 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0008 18056 0.0000 58265 
TVAG_038250 
Small GTPases and 
Associated Proteins Ras family protein no 
 
0.0014 15389 0.0000 58309 
TVAG_370000 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0007 18677 0.0000 58376 
TVAG_185080 
Small GTPases and 
Associated Proteins hypothetical protein no 
 
0.0005 20751 0.0000 58834 
TVAG_259320 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0008 17912 0.0000 58863 
TVAG_038190 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0003 22818 0.0000 59091 
TVAG_528800 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0043 11139 0.0000 59095 
TVAG_286490 
Small GTPases and 
Associated Proteins small GTP-binding protein, putative no 
 
0.0000 45618 0.0000 59338 
TVAG_099490 Sugar Metabolism ROK family protein yes 
 
1.0000 46 1.0000 24 
TVAG_442070 Sugar Metabolism ROK family protein no 
 
0.9979 170 0.9996 63 
TVAG_491670 Sugar Metabolism malic enzyme, putative no 
 
0.1645 3191 0.9773 207 
TVAG_054830 Sugar Metabolism Phosphoglucomutase/phosphomannomutase no 
 
0.8349 899 0.9681 239 
TVAG_293770 Sugar Metabolism Phosphofructokinase family protein no 
 
0.4768 1739 0.9551 261 
TVAG_462920 Sugar Metabolism Phosphofructokinase family protein no 
 
0.0492 5140 0.8455 407 
TVAG_496160 Sugar Metabolism Phosphofructokinase family protein no 
 
0.0112 8287 0.8378 411 
TVAG_391760 Sugar Metabolism Phosphofructokinase family protein no 
 
0.9949 236 0.8229 424 
TVAG_205910 Sugar Metabolism Phosphoglucomutase/phosphomannomutase no 
 
0.8286 924 0.7084 522 
TVAG_258220 Sugar Metabolism glycosyl transferase, group 1 family protein no 
 
0.9987 153 0.6230 605 
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TVAG_073860 Sugar Metabolism pyruvate, phosphate dikinase family protein no 
 
0.4316 1908 0.6168 609 
TVAG_006140 Sugar Metabolism 
6-phosphogluconate dehydrogenase, 
putative no 
 
0.6273 1395 0.5286 708 
TVAG_263740 Sugar Metabolism enolase family protein no 
 
0.0653 4624 0.2764 1054 
TVAG_430830 Sugar Metabolism 
pi-dependent fructose 6-P 1-
phosphotransferase no 
 
0.1838 3025 0.1604 1375 
TVAG_079260 Sugar Metabolism 
Pi-dependent fructose 6-P 1-
phosphotransferase no 
 
0.6325 1384 0.0977 1683 
TVAG_212020 Sugar Metabolism transketolase family protein no 
 
0.0079 9220 0.0883 1747 
TVAG_253650 Sugar Metabolism malate dehydrogenase, putative no 
 
0.8081 986 0.0490 2336 
TVAG_276310 Sugar Metabolism 
1,4-alpha-glucan branching enz. IIB, 
chloroplast put. no 
 
0.1371 3460 0.0322 2722 
TVAG_154680 Sugar Metabolism 4-alpha-glucanotransferase family protein no 
 
0.0128 7946 0.0253 3044 
TVAG_282580 Sugar Metabolism phosphoglycerate mutase family protein no 
 
0.0000 46810 0.0096 4739 
TVAG_464170 Sugar Metabolism enolase 4, putative no 
 
0.9253 640 0.0077 5169 
TVAG_373720 Sugar Metabolism pyruvate kinase family protein no 
 
0.0270 6302 0.0053 6065 
TVAG_045010 Sugar Metabolism hypothetical protein no 
 
0.7728 1074 0.0032 7641 
TVAG_043500 Sugar Metabolism enolase 3, putative no negative 0.0000 34003 0.0031 7735 
TVAG_222040 Sugar Metabolism 4-alpha-glucanotransferase family protein no 
 
0.8325 908 0.0030 7921 
TVAG_204360 Sugar Metabolism malate dehydrogenase, putative no 
 
0.8687 820 0.0029 7961 
TVAG_226870 Sugar Metabolism 4-alpha-glucanotransferase family protein no 
 
0.0011 16578 0.0020 9294 
TVAG_113710 Sugar Metabolism phosphoglycerate mutase, putative no 
 
0.0011 16377 0.0015 10172 
TVAG_329460 Sugar Metabolism enolase 2, putative no 
 
0.0001 29225 0.0006 14342 
TVAG_157940 Sugar Metabolism 4-alpha-glucanotransferase family protein no 
 
0.0019 14222 0.0003 17589 
TVAG_348330 Sugar Metabolism glycogen phosphorylase no 
 
0.0066 9740 0.0001 23690 
TVAG_204370 Sugar Metabolism hypothetical protein no 
 
0.0004 21928 0.0001 24539 
TVAG_092750 Sugar Metabolism hypothetical protein no 
 
0.0000 37900 0.0001 25490 
TVAG_146910 Sugar Metabolism hypothetical protein no 
 
0.0001 27095 0.0001 27744 
TVAG_397250 Sugar Metabolism hypothetical protein no 
 
0.0019 14217 0.0000 33752 
TVAG_381690 Sugar Metabolism AT5g28840/F7P1_20, putative no 
 
0.0002 24848 0.0000 35357 
TVAG_336940 Sugar Metabolism hypothetical protein no 
 
0.0001 30727 0.0000 35567 
TVAG_191140 Sugar Metabolism Starch binding domain containing protein no 
 
0.0598 4775 0.0000 37733 
TVAG_268050 Sugar Metabolism Phosphoglycerate kinase, putative no negative 0.0000 51404 0.0000 42928 
TVAG_383940 Sugar Metabolism Phosphoglycerate kinase, putative no 
 
0.0000 37238 0.0000 44491 
TVAG_061930 Sugar Metabolism 
glucose-6-phosphate isomerase family 
protein no negative 0.0000 46152 0.0000 49424 
TVAG_360700 Sugar Metabolism fructose-1,6-bisphosphate aldolase, putative no 
 
0.0000 57503 0.0000 53276 
TVAG_043060 Sugar Metabolism fructose-1,6-bisphosphate aldolase no 
 
0.0000 55620 0.0000 56270 
TVAG_300000 Sugar Metabolism fructose-1,6-bisphosphate aldolase, putative no 
 
0.0000 57896 0.0000 56380 
TVAG_148040 Vesicle Association ADP-ribosylation factor 1, putative no 
 
0.0000 34190 0.0009 12059 
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TVAG_369020 Vesicle Association Region in Clathrin and VPS family protein no 
 
0.0010 16820 0.0009 12151 
TVAG_249080 Vesicle Association Synaptobrevin family protein no 
 
0.0449 5302 0.0004 15876 
TVAG_450230 Vesicle Association 
Adaptor complexes medium subunit family 
protein no 
 
0.0002 26274 0.0002 18908 
TVAG_071140 Vesicle Association 
Clathrin adaptor complex small chain family 
protein no 
 
0.0000 39920 0.0002 19793 
TVAG_562550 Vesicle Association clathrin heavy chain-related protein no 
 
0.0000 41156 0.0001 27539 
TVAG_064150 Vesicle Association ADP-ribosylation factor, putative no 
 
0.0000 34577 0.0000 30636 
TVAG_547230 Vesicle Association Adaptin N terminal region family protein no 
 
0.0000 40813 0.0000 31616 
TVAG_369030 Vesicle Association Clathrin and VPS domain-containing protein no 
 
0.0000 40440 0.0000 33621 
TVAG_379690 Vesicle Association 
Clathrin adaptor complex small chain family 
protein no 
 
0.0000 35510 0.0000 37967 
TVAG_044240 Vesicle Association Adaptin N terminal region family protein no 
 
0.0019 14100 0.0000 43636 
TVAG_532880 Vesicle Association Clathrin and VPS domain-containing protein no 
 
0.0006 19155 0.0000 57151 
Supplementary Table 2- 2. Predicted MOT+ and MOT- scores of identified 
hydrogenosomal proteins. Predicted MOT+ and MOT- scores are assigned to proteins 
identified in the T. vaginalis hydrogenosome proteome (Schneider et al., 2011). Scores and ranks 
from Burstein et al., 2012 were matched to each protein. In addition, the presence or absence of 
recognized hydrogenosome targeting sequence (HTS) is indicated (yes or no). Burstein et al. 
used certain proteins as true positives, as they had been previously found to localize to the 
hydrogenosome. These are annotated as “positive” in the “Class in training set” column. Those 
indicated as “negative” are proteins believed to be strictly cytosolic based on TrichDB 
annotation and GO analysis. Ribosomal proteins were classified as negative, especially as protein 
synthesis does not happen in the hydrogenosome. Interestingly, some ribosomal proteins and few 
other “negative” proteins were found in this proteome, and indicated as “negative”; all other 
proteins that were not used in training the algorithm are blank.   
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Abstract
Trichomonas vaginalis (Tv) is an extracellular protozoan parasite that causes the most com-
mon non-viral sexually transmitted infection: trichomoniasis. While acute symptoms in
women may include vaginitis, infections are often asymptomatic, but can persist and are
associated with medical complications including increased HIV susceptibility, infertility, pre-
term labor, and higher incidence of cervical cancer. Heightened inflammation resulting from
Tv infection could account for these complications. Effective cellular immune responses to
Tv have not been characterized, and re-infection is common, suggesting a dysfunctional
adaptive immune response. Using primary human leukocyte components, we have estab-
lished an in vitro co-culture system to assess the interaction between Tv and the cells of the
human immune system. We determined that in vitro, Tv is able to lyse T-cells and B-cells,
showing a preference for B-cells. We also found that Tv lysis of lymphocytes was mediated
by contact-dependent and soluble factors. Tv lysis of monocytes is far less efficient, and
almost entirely contact-dependent. Interestingly, a common symbiont of Tv,Mycoplasma
hominis, did not affect cytolytic activity of the parasite, but had a major impact on cytokine
responses.M. hominis enabled more diverse inflammatory cytokine secretion in response
to Tv and, of the cytokines tested, Tv strains cleared ofM. hominis induced only IL-8 secre-
tion from monocytes. The quality of the adaptive immune response to Tv is therefore likely
influenced by Tv symbionts, commensals, and concomitant infections, and may be further
complicated by direct parasite lysis of effector immune cells.
Author Summary
The unicellular parasite Trichomonas vaginalis (Tv) causes the most common non-viral
sexually transmitted infection worldwide, with approximately one quarter of a billion peo-
ple infected annually. Tv infections are linked to pre-term and low-weight infant birth,
increased susceptibility to and transmission of HIV infection, and increased aggressiveness
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of urogenital tract cancers. How the immune system responds to Tv, and how the parasite
persists in the presence of the immune system, is not well understood. We show that Tv
can kill human immune cells. We found that a clinical isolate of Tv is more efficient at kill-
ing immune cells than a laboratory-adapted strain, and that Tv preferentially targets B-
cells. This killing activity is mediated by both contact-dependent and soluble factors. Kill-
ing immune cells could allow Tv to subvert or disable the immune system. Conversely, we
found that cells of the immune system respond to Tv by secreting soluble inflammatory
mediators called cytokines, mainly interleukin-8. However, these cells secrete greater
amounts, and a broader profile of inflammatory cytokines when they encounter Tv har-
boring its symbiont bacterium,Mycoplasma hominis. We conclude that Tvmay interact
with immune cells in different ways, depending on the strain of Tv and the symbiont it
harbors.
Introduction
Trichomonas vaginalis (Tv) is a unicellular, aerotolerant, flagellated protozoan parasite that is
an obligate extracellular pathogen, restricted to humans [1]. Tv adheres to and lyses host epi-
thelial cells [2], followed by phagocytosis of cellular contents [3]. Tv destruction of the epithe-
lial layer in the female reproductive tract (FRT) is apparent in the clinical presentation of
“strawberry cervix,” in which red lesions are visible on the external surface of the cervix of
infected women [1]. Once thought to be a commensal member of the vaginal microflora, Tv is
now known to be pathogenic and is responsible for the most common non-viral sexually trans-
mitted infection (STI) in the United States and worldwide: trichomoniasis [4]. The WHO
reports ~275 million cases annually [1], but this number is likely a gross underestimation, as
the CDC estimates that at least 50% percent of cases are asymptomatic. In the United States, an
estimated 8–10 million new infections occur annually [5]. Alarmingly, trichomoniasis is on the
rise in adolescents [6], and in dense urban areas prevalence can be as high as 50% [7]. Because
Tv responds well to metronidazole, an antibiotic that specifically kills anaerobic cells [1], most
symptomatic cases are successfully treated. However, emergence of metronidazole-resistant
strains continues to increase [4,8–12], and metronidazole treatment may not efficacious for
preventing pregnancy-related Tv complications [13,14]. Moreover, the association of subclini-
cal infection with complications affecting women’s reproductive health [6,15] necessitates a
better understanding of how Tv causes disease, and how the immune system responds to the
parasite.
Trichomoniasis is associated with increased susceptibility to HIV, HSV-2, pelvic inflamma-
tory disorder, pre-term and low-weight infant birth, infertility, and endometritis [15]. Tv infec-
tion is also associated with bacterial vaginosis, suggesting a disruption of the microflora [6]. In
addition, Tv infection or serostatus has been correlated with an increased incidence of cervical
cancer [16,17], especially invasive types [18–20]. Although Tv is typically asymptomatic in
men [21], they are commonly infected and trichomonads can be detected in prostate tissue
[22]. Tv infection in men has been linked to invasive forms of prostate cancer [23], and infertil-
ity [24]. It is thought that Tv- induced inflammation can exacerbate existing neoplastic lesions,
increasing chances of malignancy [25,26].
Tv often co-exists with a symbiont bacterium,Mycoplasma hominis [27]. Otherwise axenic
cultures of clinical isolates and lab strains of Tv often containM. hominis, growing both exter-
nally to and within Tv [28,29]. This is unlikely to be an artifact of laboratory-introduced con-
tamination, as a recent study of clinical isolates found the prevalence ofM. hominis in Tv
Trichomonas vaginalis Interaction with Human Leukocytes
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004913 August 16, 2016 2 / 19
Competing Interests: The authors have declared
that no competing interests exist.
84 
 
 
isolates to be 56% [30]. The prevalence of the biological association of Tv andM. hominis
underscores the epidemiological relevance of studying Tv strains containingM. hominis.
Despite the association of Tv with numerous complications of a putative inflammatory eti-
ology, how the immune system responds to and clears Tv is not well understood. Neutrophils
are usually abundant during acute infection [31,32]. Antibodies can be detected in sera of
infected persons [1,33,34], and after experimental challenge in a mouse model [35]. Peripheral
blood mononuclear cells (PBMC) from infected persons proliferate in vitro in response to re-
call antigen [36], and CD4+T cells were shown to be present after experimental mouse infec-
tion [35]. However, partner re-infection is common [1], indicating that there may be inade-
quate formation of immunological memory, or that Tv subverts effective adaptive immune
responses. Tv has also been shown to induce IL-8 secretion from primary human monocytes
[37]. In addition, the Tv symbiontMycoplasma hominis has been shown to enable induction of
an array of inflammatory cytokines in a macrophage cell line following Tv encounter [38].
However, studies examining the cytokine profile following Tv encounter with primary human
monocytes have yet to be performed.
Tv shares a niche with numerous other commensal microorganisms in the FRT [39], and
infection is often concomitant with other STIs [1,5]. Leukocytes populate mucosal tissues of
the FRT [40], where they manage responses to commensals and other STIs. Leukocytes are pre-
dominant in the lamina propria, but may also follow trans-epithelial chemokine signals to
home to the luminal side of the mucosa [41]. Tvmay therefore encounter leukocytes while
adhering to epithelial cells on the luminal side of the FRT, or approaching the lamina propria
as the epithelial layer is breached by Tv cytolysis of epithelial cells. Tv has been demonstrated
to phagocytose human leukocytes [42], indicating that direct leukocyte killing could contribute
to Tv immune subversion; however, the efficiency, kinetics, and cell-specificity of this process
is unknown.
Characterizing the type of immune response that Tv stimulates and determining whether
Tv cytotoxic activity can kill leukocytes will be important to understanding why Tv is often per-
sistent, how Tv infection may lead to inflammatory sequelae, and how Tv infection may affect
the microbiome in the FRT. Tv is a human-specific pathogen, and most attempts at experimen-
tal mouse infection have failed to sustain adequate parasite titers, with the exception of a model
using pre-treatment with estrogen and dexamethasone [43], both of which are immunosup-
pressive and therefore undesirable for analysis of immune function. In addition, specific host-
surface proteins are implicated in pathogenesis [44], so using cells of the natural host for these
studies is optimal. Using primary human leukocytes, here we show that Tv is able to kill
immune effector cells, showing a preference for B-cells, and that cytokine responses induced by
the parasite are largely dependent on the symbiontM. hominis.
Methods
Ethics statement
All work with cells from human blood donation was done in compliance with the UCLA
School of Medicine IRB Committee.
Trichomonas vaginalis strains and culture
Tv strains G3 (Beckenham, UK 1973, ATCC-PRA-98), and MSA1132 (Mt. Dora, Fla, USA
2008) were grown in TYMmedium supplemented with 10% horse serum (Sigma), 10 U/ml
penicillin (Invitrogen), 10 μg/ml streptomycin (Invitrogen), 180 μM ferrous ammonium sul-
fate, and 28 μM sulfosalicylic acid [45] at 37°C. Strains were passaged daily and maintained at
an approximate concentration of 1 x 105–2 x 106 cells/ mL. To generateM. hominis free strains,
Trichomonas vaginalis Interaction with Human Leukocytes
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Tv was grown in the presence of 50 μg/ml chloramphenicol and 5 μg/ml tetracycline (Sigma-
Aldrich), supplemented daily for at least 5 days andM. hominis clearance was confirmed by
PCR as described below. To generate dead, intact controls, Tv was counted, and then reconsti-
tuted in complete RPMI media, and rendered dead—but intact—by treatment at 65°C for 1
hour, followed by 3 freeze-thaw cycles [46]. Trichomonads were confirmed by microscopy to
be immobile and intact and flow cytometry analysis using Zombie Red dead-cell exclusion dye
(Biolegend) confirmed that trichomonads were not viable after this treatment.
Primary human cell acquisition and culture
Primary human peripheral blood mononuclear cells (PBMC) were isolated from leukopacks or
trima filters using Ficoll gradient. Blood was obtained from 32 de-identified, healthy donors
from the UCLA Virology Core using a UCLA Institutional Review Board approved protocol.
Monocytes were isolated based on adherence to plastic (for monocytes used in cytotoxicity
experiments) or by Rosette Sep © negative isolation (Stem Cell technologies) (for monocytes
used in cytokine secretion experiments). PBMC and monocytes were frozen directly after puri-
fication and used the day they were thawed. All experiments with PBMC and monocytes were
done using RPMI 1640 media supplemented with 10% Fetal Bovine Serum, Pen/Strep, Gluta-
MAX, and MEM non-essential amino acids, (Life Technologies), and incubated at 37°C with
5% CO2.
In vitro differentiation of human monocyte-derived macrophages
(HMDM)
Primary human PBMC were isolated from a trima filters using Ficoll gradient using blood
from donors at the UCLA Virology Core. Monocytes were separated based on adherence to
plastic and were plated at 2.7 x 105 cells/ml. 20 ng/ml of GM-CSF (Biolegend) was added for 4
days to induce macrophage differentiation. The differentiation was verified by staining with
anti- CD14-PE (Invitrogen- MHCD14014) and an increase in forward scatter (size).
Flow-Cytometry based cytotoxicity assay
Brooks et al. demonstrated that Tv- host cell co-cultures are suitable for flow cytometry analy-
sis [47]. As the similar size of Tv and leukocytes confounds cell discernment via size and scatter
properties alone, we utilized differential dye staining. PBMC were labeled with Carboxyfluores-
cein succinimidyl ester (CFSE) (Biolegend) at 1:2000 for 3 minutes according to the manufac-
turer’s instructions and then washed and plated at 2.5 x 105 cells/well in 100 μl in u-bottom 96
well plates. Tv was labeled with Cell Tracker Blue © (Molecular Probes), according to the man-
ufacturer’s instructions, and then allowed to recover in complete TYMmedia for 45 minutes- 2
hours. Tv was then reconstituted in complete RPMI media and added directly to wells contain-
ing PBMC at the indicated multiplicities of infection (MOI) for the indicated period of time.
After incubation, cells were stained with anti-CD3 APC clone HIT3a and anti-CD19 PeCy7
clone HIN19 (both from Biolegend) at 1 μg/ml in FACS buffer (PBS with 5% FBS and 0.1%
sodium azide) on ice for 30 minutes. Cells were then washed and resuspended in FACS buffer
and analyzed within 2 hours on an LSR Fortessa © (Becton-Dickinson) at the UCLA Broad
Stem Cell Research Center Flow Cytometry core facility. Directly before sample acquisition,
5 μl of Bright Count © counting beads (Life Technologies) was added to each sample. Data
were analyzed using FlowJo (Treestar), and counts of each population (Tv, T-cell or B-cell)
were determined according to the gating strategy is shown in S1 Fig. Cell counts were uni-
formly normalized to 2,000 beads, and percent death was calculated as ((# of B-cells in PBMC
alone condition—# of B-cells in co-culture condition) / # of B-cells in PBMC alone condition)
Trichomonas vaginalis Interaction with Human Leukocytes
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!100, for B-cells (same analysis was done for T-cells) or as ((# of parasites in parasites alone
condition—# of parasites in co-culture condition) / # of parasites in parasites alone condition)!
100 for Tv. Zombie Red dead-cell exclusion dye (Biolegend) was added to preliminary cytotox-
icity experiments to assure that live cell gates based on forward and side scatter did not include
dead cells (S2 Fig), and then found to be redundant since dead cells disappear from the live cell
scatter plot completely. Zombie Red staining was therefore excluded in subsequent experi-
ments for simplicity. For transwell cytotoxicity experiments, an HTS Transwell—96 well plate
(Corning) with 0.4 μm polycarbonate membrane was used. PBMC were placed in the bottom,
receiver plate, which was spun down and processed as described above after the co-culture.
Two-tailed, unpaired student’s T-test was done to determine statistical significance between
conditions, when relevant.
Lactate dehydrogenase-based cytotoxicity assay
Monocytes isolated based on plastic adherence as described above were plated at 5 x 105 cells/
well in 96-well flat-bottom plates. Tv was reconstituted in complete RPMI media as described
above and added at the indicated MOI for the indicated period of time. After the co-culture,
monocyte death was measured by determining mammalian-specific lactate dehydrogenase
(LDH) release using the CytoTox-One © homogeneous membrane integrity assay (Promega)
according to the manufacturer’s instructions. Samples were read on a Victor3 1420 plate reader
(Perkin-Elmer) to generate mean fluorescence intensity (MFI) values correlating with LDH
presence in the supernatants. Percent death was calculated as (MFI from co-culture superna-
tants- MFI from live monocytes alone supernatants)/ (MFI from detergent solubilized mono-
cytes alone supernatants–MFI from live monocytes alone supernatants) !100. Transwell
cytotoxicity experiments were conducted as described above.
Cytokine analysis
Human monocytes isolated by Rosette Sep © negative selection were plated at 5 x 104 cells/
well in 96-well u-bottom plates. Tv was counted, and then reconstituted in complete RPMI
media, and rendered dead, but intact as described above. Dead, intact Tv were then added to
monocytes, or human monocyte derived macrophages (HMDM) at an MOI (multiplicity of
infection) of 1, and allowed to incubate overnight (16 hours). Positive controls were 100 ng/ml
LPS (sigma) 10 μg/ml poly (I:C) (Tocris) or 1000 U/ml IFN gamma (Biolegend). Subsequently
plates were centrifuged and supernatants were harvested and frozen at -80°C. Supernatants
were then thawed on ice and analyzed using Cytometric Bead Array (Becton-Dickenson) for
IL-8, IL-6, IL-1β, TNFα, and IL-12 according to the manufacturer’s instructions. IL-6, IL-1β,
and IL-12 were multiplexed, and IL-8 was measured separately on supernatants diluted 1:100.
Data were analyzed using FlowJo (Treestar) to determine MFI, which was normalized to abso-
lute concentrations according to a standard curve generated using lyophilized protein provided
with the kit. IL-23 was measured using Legend Max Human IL-23 (p19/p40) ELISA kit with
pre-coated wells (Biolegend) according to the manufacturer’s instructions. Wells were read
using a Victor3 1420 plate reader (Perkin-Elmer), and MFI was normalized as described above.
M. hominis analysis in T. vaginalis strains
Dense 15ml cultures of Tv were lysed using a solution of 8M urea, 2% sarkosyl, 0.15M NaCl,
0.001M EDTA, and 0.1M Tris HCL pH7.5, and DNA was extracted using phenol: chloroform:
ISA (Amresco), precipitated with isopropanol, and reconstituted in 10mM Tris pH8+ RNase.
Then PCR was performed on Tv DNA using the following primer pairs: (1)M. hominis specific
primers: 5’ CAA TGG CTA ATG CCG GAT ACG C 3’ and 5’ GGT ACC GTC AGT CTG
Trichomonas vaginalis Interaction with Human Leukocytes
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CAA T 3’ [48] and (2) universal 16S rDNA primers: 5’ AGA GTT TGA TCC TGG CTC AG 3’
and 5’ GGA CTA CCA GGG TAT CTA AT 3’ (Greg James, PCR for Clinical Microbiology,
2010). PCR products were sequenced (Genewiz), and resultant sequences were aligned using
NCBI nucleotide BLAST and ApE software and confidence peaks were examined in comparison
toM. hominis sequence. These analysis were done on non-clonal Tv strains G3 andMSA1132
either cured of residentM. hominis strains or prior to curing with antibiotic treatment. Identical
M. hominis sequences were derived using uncured strains in replicate experiments.
Results
Trichomonas vaginalis (Tv) is known to lyse cervical and prostate epithelial cells [2]. Since leu-
kocytes are present in the genital mucosa [40], and in the lamina propria directly beneath the
epithelial layer [41], we asked whether Tv is able to kill leukocytes. To assess this, we set up an
in vitro co-culture system of Tv with primary human peripheral blood mononuclear cells
(PBMC), and then determined numbers of surviving cells using flow cytometry following the
co-culture. Prior to the co-culture, Tv were labeled with Cell Tracker Blue © (CTB), and PBMC
were labeled with carboxyfluorescein succinimidyl ester (CFSE). After co-culture, wells were
stained with anti-CD3 and anti-CD19 to identify T-cells and B-cells, respectively. Directly
before flow cytometry analysis, counting beads were added to wells for sample-to-sample vol-
ume normalization. Counts of live CTB+ CFSE- (Tv), CFSE+CD3+ (T-cells) and CFSE+CD19
+ (B-cells) events were then determined and normalized to PBMC alone, or Tv alone controls
to calculate percent death of each population. Using this system, we first tested a common labo-
ratory adapted strain of Tv (G3) [49] compared to a relatively recent clinical isolate of Tv
(MSA1132) [2]. We observed that clinical strain MSA1132 was able to kill ~30% of T cells and
~70% of B-cells in the co-culture, using a multiplicity of infection (MOI) of 0.5 (1:2 Tv: host
cell ratio). On the other hand, Tv lab strain G3 did not kill T-cells under these conditions and
demonstrated only minimal killing of B-cells (Fig 1A).
Having determined that TvMSA1132 is cytotoxic towards lymphocytes, we next addressed
the efficiency and kinetics of Tv lymphotoxic activity. The amount of Tv needed to lyse lym-
phocytes was determined by performing the cytotoxicity assay at various MOI. We found mod-
erate levels of lymphocyte death occurring at MOI of 0.25 (1:4, Tv: host cells), whereas at MOI
2 (2:1, Tv: host cell), we found almost complete killing of B-cells and ~75% killing of T-cells
(Fig 1B). Lymphocyte killing requires live parasites, as co-cultures containing dead, intact Tv at
the same MOI did not result in any lymphocyte death (S3 Fig). Next, we determined how fast
Tv killing of lymphocytes occurs by performing cytotoxicity assays at an intermediate MOI
(0.5), and assessing lymphocyte death at various time points during the co-culture. We found
that lymphocyte death was not rapid, and required 2 hours to achieve low levels, and 5–6 hours
to achieve relatively high levels of death (Fig 1C). Using TvMSA1132 as a model clinical strain,
these data indicate that some clinical strains of Tv possess lymphotoxic activity and require sev-
eral hours and high parasite titers to achieve maximal killing; nevertheless moderate lympho-
toxic effects are observed at shorter time points and lower parasite titers. Also, while there was
some donor-to-donor variability in susceptibility to Tv cytotoxicity, B-cells were significantly
more susceptible (S4A Fig).
Tv likely comes into direct contact with lymphocytes at the luminal side of the vaginal
mucosa and also in the lamina propria after tissue invasion associated with lysis of the epithe-
lial layer. However, Tv killing of lymphocytes could have an extended effect in tissues if it were
mediated by soluble factors. We therefore asked whether Tv lymphotoxic activity was contact-
dependent, or mediated by soluble factors by performing our cytotoxicity assays utilizing a
trans-well insert system with a 0.4 μm porous membrane. As Tv is 7–10 μm in diameter, the
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parasite cannot pass through [2]. In conditions where PBMC and Tv were cultured together,
death of T-cells and B-cells was observed at levels similar to that shown in Fig 1. However,
when Tv and PBMC were placed in separate chambers there was an approximately 2-fold
decrease in death of T-cells and B-cells (Fig 2A and 2B). The significant difference in lympho-
toxic activity observed when parasite and lymphocytes were in the same chamber or separated
by a membrane indicates that killing of B-cells and T-cells by Tv is mediated by both contact
dependent and soluble factors.
We next asked whether Tv can lyse monocytes. To avoid variability arising from adherence
of activated monocytes to plastic, we measured levels of lactate dehydrogenase (LDH) released
in the culture supernatants upon lysis of monocytes, instead of using flow cytometry. Tv killing
Fig 1. Lymphotoxic activity of Tv. (A) PBMC and Tv strains TvG3 (laboratory adapted) or TvMSA1132 (clinical isolate) were
differentially labeled with CFSE or Cell Tracker Blue, respectively and co-cultured at an MOI of 0.5 for 4 hours. Cells were then
stained with anti-CD3 and anti-CD19 to detect T-cells or B-cells, respectively, and lymphocyte death was assessed with flow
cytometry analysis. (B) Killing of lymphocytes by TvMSA1132 was assessed as in (A) at the indicated MOI for 4 hours. (C) Killing of
lymphocytes by TvMSA1132 was assessed as in (A) at an MOI 0.5 for the indicated period of time. All data in (A-C) are averages
with standard deviation of triplicate wells and representative of at least 3 donors/ independent experiments.
doi:10.1371/journal.pntd.0004913.g001
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of monocytes was found to be inefficient, with only ~20% death of monocytes observed at an
MOI of 2 (2 Tv:1 monocyte) (Fig 3A). A 1–6 hour time course was used to assess the kinetics of
killing, and death was found to be linear over 6 hours (Fig 3B). It is notable that prolonged co-
incubation did not significantly increase monocyte death even after 24 hour. While there was
some donor-to-donor variability, Tv killing of monocytes was always less efficient than that of
lymphocytes (S4B Fig). To determine whether Tv lysis of monocytes is contact-dependent,
cytotoxicity assays were performed using the transwell system. We found that unlike that
observed for killing of lymphocytes (Fig 2), separation of Tv from monocytes almost
completely abolished cytotoxic activity (Fig 3C). Together these data indicate that Tv killing of
monocytes is inefficient and primarily contact-dependent.
Since symbionts often increase fitness of their hosts, we next asked whether a common sym-
biont of Tv,M. hominis, affects the ability of Tv to kill leukocytes. TvMSA1132 naturally con-
tainsM. hominis, thus to generate isogenic strains that either harbor the symbiont or not, we
cultured TvMSA1132 for 1 week either untreated, or in the presence of chloramphenicol and
tetracycline. PCR usingM. hominis-specific primers was then conducted to confirm thatM.
hominis was undetectable in the culture treated with additional antibiotics (S5 Fig). Further-
more, sequencing the products generated by PCR using universal 16S bacterial primers on our
untreated cultures confirmed thatM. hominis is the only bacterial species present in the
untreated culture. We then used the untreated (M. hominis+) and antibiotic treated (M. homi-
nis-) strains side-by-side in leukocyte cytotoxicity assays. We found that the ability to kill T-
cells, B-cells or monocytes was not significantly different, indicating thatM. hominis does not
confer greater leukotoxic activity to Tv (Fig 4A–4C).
Having observed that Tv is potentially able to modulate immune responses by killing lym-
phocytes, we next asked the converse question: what type of immune response is mounted
against Tv? To address this, we assayed for the presence of several cytokines secreted from pri-
mary human monocytes after overnight exposure to Tv. To prevent Tv killing of monocytes
from affecting the results, we made dead, intact preparations of Tv before co-culture and
Fig 2. Tv lymphotoxic activity is mediated by contact dependent and soluble factors. PBMC and TvMSA1132 were co-
cultured and lymphocyte death was assessed as described in Fig 1 at an MOI of 0.5 for 4 hours in a transwell apparatus. PBMC
were placed in the bottom chamber and TvMSA1132 were placed either with PBMC in the bottom chamber (together) or in a top
chamber with shared media, but separated by a 0.4 μm porous membrane (separate). Percent death in the bottom chamber was
then assessed for B-cells (A) and T-cells (B). Data shown are averages of triplicate wells with standard deviation, and are
representative of 4 donors and 2 independent experiments.
doi:10.1371/journal.pntd.0004913.g002
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confirmed that no monocyte death occurred after incubation with dead Tv. Fiori and col-
leagues recently showed thatM. hominis dramatically increased the amount of pro-inflamma-
tory cytokine induced from a human macrophage-like cell line [38]. We were able to
reproduce these results using primary human monocyte derived macrophages (HMDM) (S6
Fig). We therefore compared cytokine responses induced from untreated (M. hominis+) or
additional antibiotic treated (M. hominis-) strains using fresh, naïve human monocytes. We
also compared the responses against the laboratory adapted (TvG3) versus the clinical
(TvMSA1132) strain. Levels of cytokines known to support Th1 responses (IL-12) and Th17
responses (IL-6, IL-1β, and IL-23) were assessed. IL-8, a broadly inflammatory, neutrophil-
Fig 3. Tv cytotoxicity towardsmonocytes is inefficient and contact-dependent. (A) Primary humanmonocytes were co-cultured
with TvMSA1132 at the indicated MOI. Monocyte death was assessed by detecting the release of mammalian lactate dehydrogenase
(LDH) into culture supernatants after 4 hours. (B) Primary human monocytes were co-cultured with TvMSA1132 at MOI 0.5 for the
indicated times and percent death was determined. (C) Killing of monocytes by TvMSA1132 at an MOI of 2 was determined using a
transwell apparatus as described in Figure legend 2, except monocytes were used instead of lymphocytes. LDH was measured in
culture supernatants after 4 hours. All data in shown (A-C) are averages of triplicate wells with standard deviation, and are
representative of at least 3 donors/independent experiments.
doi:10.1371/journal.pntd.0004913.g003
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recruiting chemokine previously reported to be highly secreted following Tv encounter
[31,32,37] was also measured. All strains of Tv tested induced IL-8 secretion over background
(Fig 5A). Notably, the presence ofM. hominis greatly increased IL-8 induction, relative to iso-
genic strains lackingM. hominis (Fig 5A), and enabled induction of IL-6 and IL-1β which were
otherwise not detectable in response to Tv alone (Fig 5B and 5C). In contrast, neitherM. homi-
nis positive nor negative parasites induced detectable IL-23 or IL-12 secretion (Fig 5D and 5E).
No difference was observed in the immunogenicity of laboratory-adapted strain TvG3 com-
pared to clinical strain TvMSA1132 (Fig 5A–5E). Together these analyses indicate that IL-8 is
the dominant cytokine response to Tv, both in the presence and absence ofM. hominis. The
Fig 4. Tv symbiontMycoplasma hominis does not affect Tv leukotoxic activity. Killing of B-cells (A), T-cells (B), or monocytes (C)
by TvMSA1132 was determined at an MOI 0.5 for 4 hours. Prior to the cytotoxicity assay, TvMSA1132 was either cultured in the
presence (M. hominis -) or absence (M. hominis +) of additional antibiotics. Data shown are average of triplicate wells with standard
deviation, and are representative of 3 donors/ independent experiments.
doi:10.1371/journal.pntd.0004913.g004
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data also show that the symbiontM. hominis greatly increases the induction of inflammatory
cytokines IL-6 and IL-1β, in addition to IL-8. This increased immunogenicity may be instru-
mental in triggering adaptive immune responses that would not normally be mounted against
Tv in the absence of the symbiont.
Discussion
Despite the numerous inflammatory complications associated with Tv infection, how Tv inter-
acts with the cells of the host immune system is not well characterized. Furthermore, partner
re-infection after treatment for trichomoniasis indicates a lack of effective adaptive immunity
to Tv. Using primary human leukocytes, we have demonstrated that Tv has leukotoxic activity,
that IL-8 secretion dominates the primary cytokine response to Tv infection, and that theM.
hominis symbiont is likely to play a major role in shaping more robust and diverse inflamma-
tory responses to Tv. These results form a foundation for the dissection of interactions between
Fig 5. Induction of cytokine secretion from humanmonocytes by Tv is largely dependent on the presence ofMycoplasma
hominis and is dominated by IL-8 secretion. Primary humanmonocytes were cultured with either dead intact TvG3,
TvMSA1132, unstimulated, or treated with LPS (A, B, D) or poly (I:C) (C) or LPS and IFNγ (E) for 16 hours. Prior to killing, Tv strains
were either untreated (M. hominis+) or treated with additional antibiotic to clear the symbiont (M. hominis-). Supernatants were
collected and the indicated cytokines were measured using Cytometric Bead Array (CBA) or ELISA. Data shown are average of
triplicate wells with standard deviation, and are representative of 3 donors/ independent experiments.
doi:10.1371/journal.pntd.0004913.g005
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Tv and the cells of the human immune system. These studies are the first to examine how pri-
mary human leukocytes respond to Tv, and to assess Tv leukotoxic activity, with attention to
strain specificity, host cell-preference, timing, and dosage. These analyses have also interro-
gated the contribution of the symbiontM. hominis to the pathogenesis and immunogenicity of
Tv using primary immune cells. We found that immune responses against Tvmay be modu-
lated by leukotoxic activity of the parasite as well as the presence ofM. hominis. These results
suggest potential explanations for the considerable variability in Tv clinical presentation, path-
ogenicity, and inflammatory sequelae.
The leukotoxic activity of Tv reported here may be important in subverting immune
responses, or in modulating the leukocyte repertoire in the vaginal mucosa, where leukocytes
may control concomitant STIs and commensal micro-organisms [41]. We sought to determine
which cells among PBMC are primary targets of the parasite and found that Tv demonstrates a
preference for killing B-cells, followed by T-cells, and is very inefficient at killing monocytes.
Interestingly, while the cell-type preference was maintained in all donors tested, there was
some variability in overall susceptibility of leukocytes to Tv- mediated killing (S4 Fig), which
could account for variation in symptoms and sequelae in the clinic. It is interesting that B-cells
are the most vulnerable leukocyte in the presence of Tv, as humoral immunity is likely to be
important in host defense against Tv: a large extracellular eukaryotic pathogen. Antibodies
against Tv can be detected in sera and vaginal washes of infected individuals [1,34,50], indicat-
ing that humoral immunity is formed against the parasite. Furthermore, Tv strains that do not
harbor the symbiontM. hominis do not induce detectable levels of IL-1β, IL-6 or IL-12 secre-
tion from monocytes (Fig 5B, 5C and 5E), suggesting formation of default Th2 responses to Tv,
at least in the absence of symbiontM. hominis. Since ~50% Tv clinical isolates lackM. hominis
[27,30], Th2 responses could predominate in these cases. Killing of antibody-producing B-cells
(such as those at the mucosa secreting IgA [51] could therefore be a way for the parasite to sub-
vert immune clearance. Interestingly, Tv proteases are reported to cleave IgG and secretory IgA
[52] and Tv exhibits antigenic variation [53], both consistent with a model of humoral immu-
nity subversion as an evolved behavior of Tv to survive in its host. We also found that approxi-
mately 50% of Tv leukotoxic activity against B-cells was mediated by soluble factors, indicating
that the parasite may kill B-cells even if it does not come into direct contact with them, poten-
tially allowing for a broader effect of this anti-B cell activity. Contact dependent killing was also
observed, consistent with previous work showing that human PBMC can be phagocytosed by
Tv [54].
Moderate cytotoxic activity of Tv against T-cells was also detected, albeit lower than that
exhibited towards B-cells, again mediated by both contact-dependent and soluble factors (Figs
1 and 2). Tv-antigen-induced proliferation of PBMC from infected women [36] indicates that
T-cell responses are formed against Tv in vivo. Tv killing of T-cells could therefore potentially
subvert anti-Tv immune responses as well as affect the T-cell repertoire in the such that control
of concomitant STIs or commensals is dysregulated. Indeed, Tv infection is associated with
dysbiosis of microbiota in the FRT and bacterial vaginosis [55–57]. Since T-cell polarization is
a delicate and multi-factorial process involving both positive and negative feedback, Tv killing
of T-cells could have more complex downstream implications in anti-Tv immunity, on other
vaginal microflora, and on mucosal inflammation.
We observed both contact-dependent and contact-independent leukotoxic activity for the
clinical isolate TvMSA1132. Previously demonstrated phagocytosis of leukocytes [42] could
account for or contribute to the contact-dependent leukotoxic activity observed. Alternatively,
the cytotoxicity could be mediated almost entirely by soluble factors, but require close proxim-
ity; concentrations of pH and secreted effectors being effectively higher in such a microenvi-
ronment. Contact-independent killing of leukocytes by Tv has not been previously described.
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However soluble, extracellular Tv cysteine proteases have been isolated [58,59] and several
studies implicate them in Tv cytolytic mechanisms [60–63]. In addition, several genes with
homology to known pore-forming toxins are present in the Tv genome [49]. Future work to
determine the identity of soluble factors involved in Tv contact-independent killing of lympho-
cytes will be important to understand the mechanism underlying this mode of host cell
cytotoxicity.
The observation that the recent clinical isolate TvMSA1132 demonstrated dramatically
enhanced lymphotoxic activity compared to the common laboratory adapted strain TvG3 (Fig
1A) is notable. We have previously shown that Tv lysis of prostate and vaginal epithelial cells,
which is strictly contact-dependent, is highly variable among different Tv strains [2]. Strain dif-
ferences in contact-independent modes of lysis, as demonstrated here, reveal an added layer of
strain variation in pathogenic behavior, underscoring the value of using clinical strains for
studies of Tvmolecular pathogenesis, and highlighting a likely reason for the considerable clin-
ical variability in trichomoniasis presentation and outcomes. Unfortunately, the clinical symp-
toms of the patient from which TvMSA1132 was isolated are not available to allow direct
comparison of host cell toxicity in vitro with clinical outcomes. Variability between Tv andM.
hominis strains and their host cell-specific interactions may also explain why in this study we
did not find differences betweenM. hominis positive and negative Tv cultures in their ability to
kill leukocytes (Fig 4), in contrast to the enhancement of epithelial cell lysis conferred to Tv by
M. hominis observed by Vancini and colleagues [64]. This further supports a model of diverse
mechanisms underlying Tv cytotoxicity that may be strain and host cell type dependent.
In contrast to the efficient killing of lymphocytes by TvMSA1132, monocytes were refrac-
tory to killing and the cytotoxicity that was observed was almost exclusively contact-dependent
(Fig 3). Variation in the ability of Tv to kill host cells may be dependent on specific host-cell
factors that are enriched on epithelial cells [2] and B-cells, and are present at lower levels on T-
cells and monocytes. Only one host-cell receptor for mediating Tv interaction with host cells,
galectin-1, has been identified. However, knock-down of galectin-1 expression in epithelial
cells abrogated only ~20% of Tv adherence, indicating that adherence and contact-dependent
cytolysis is a multi-factorial process [44]. Future studies aimed at identifying novel host mole-
cules that confer vulnerability to contact-independent Tv killing will be important to under-
standing mechanisms of Tv leukotoxic activity.
A lack of robust cytotoxic activity towards monocytes (Fig 3) indicates that Tv does not sub-
vert cytokine secretion from myeloid cells by killing the producers. Rather, cytokine secretion
by monocytes is likely to proceed even in the presence of live, active parasites. In agreement
with Fiori and colleagues [38] we found cytokine secretion by monocytes to be remarkably
affected by the presence of the symbiontM. hominis (Fig 5). The absence of inflammatory cyto-
kine production stimulated from monocytes in the presence ofM. hominis-free Tv strains sug-
gests that Th2 responses may be formed in cases where Tv strains areM. hominis negative. As
Tv is an extracellular pathogen, and no IL-12 was induced in response to any Tv strain tested, it
seems unlikely that Th1 responses are formed against the parasite. However, in the presence of
M. hominis or other bacterial or viral antigens to provide co-stimulation in the milieu in vivo,
Th17 responses specific to Tvmay form. In humans, IL-1β, IL-6, and IL-23 support the forma-
tion or persistence of Th17 cells [65]. We saw that IL-1β and IL-6 were stimulated byM. homi-
nis-infected Tv. In contrast to that observed by Fiori et al., we did not detect significantly high
amounts of IL-23 in response toM. hominis + Tv, which potentially highlights a difference
between the THP-1 macrophage cell line that Fiori et al. used and our primary human mono-
cyte system, or that Fiori et al. used live trichomonads as opposed to our use of dead-intact
trichomonads as stimulant. Regardless, IL-23 could be present in in vivomilieus as a result of
other commensals or concomitant STIs. Indeed, IL-17 has been shown to be a major player in
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the immune response against the related parasite Giardia lamblia [66–68], and IL-22, a com-
mon cytokine associated with Th17 responses has been detected in vaginal secretions from Tv
infected patients [69]. Th17 responses are common in the mucosa, where they respond to
extracellular pathogens by recruiting neutrophils and repairing damaged epithelia [70,71], con-
sistent with FRT neutrophilia and epithelial damage associated with Tv infection.
The commensal lactobacilli, dominant in ~75% of women’s vaginal microbiomes, have been
shown to modulate Tv pathogenic properties in vitro [72]; it is conceivable that moieties pres-
ent on commensal bacteria sharing a niche with Tv could additionally affect cytokine responses
during Tv infection. Recently, additionalMycoplasma species associated with clinical strains of
Tv have been discovered [73]. Known symbionts, commensals, and concomitant STIs are likely
only the “tip-of-the-iceberg;” many other yet undefined organisms may contribute to the com-
plex ecosystem with which Tv co-operates and contends. Meta-analysis of the FRT microbiome
in the context of Tv infection, as well as development of suitable in vivomodels will be instru-
mental to more fully appreciate this diversity and test hypotheses about Tv clearance and
inflammation with a more holistic approach.
We found that both Tv strains examined, regardless ofM. hominis status, induce IL-8 secre-
tion (Fig 5) [1,31,32,37]. IL-8 is a pleiotropic cytokine [74], with a main function of recruiting
neutrophils, consistent with that observed in trichomoniasis in the clinic. Furthermore, work
in mouse models has shown that prevention of neutrophil influx is needed to establish infec-
tion [43], and primary human neutrophils were shown to swarm and attack Tv in vitro [32]
suggesting that neutrophils are crucial for control of Tv infection. However, the molecular
determinants of neutrophil-Tv interactions are not characterized. Neutrophils have a range of
highly inflammatory and destructive behaviors [75], and can even contribute to cancer micro-
environments [74]. It is possible that neutrophils may contribute to the associations of repro-
ductive complications, inflammatory pathologies, and cancers of the reproductive tract with
Tv.
These studies shed light on potential reasons for variability in Tv clinical presentation and
associated complications, suggest potential immune subversion strategies of the parasite, and
may help to inform future immunotherapy interventions. A better understanding of how Tv
interacts with the immune system will also potentiate the design of immunotherapies to aid in
scenarios of antibiotic resistance or to mitigate damaging inflammatory processes induced by
Tv infections.
Supporting Information
S1 Fig. Gating strategy used for flow cytometry- based cytotoxicity assays. (Top panels)
Total wells were analyzed for forward scatter vs. side scatter and beads, and live cells were
gated on. Beads were further gated based on A-405 positivity to more accurately ensure their
identity. (Middle panels) Live cells were further sub-gated based on CFSE+ to gate on leuko-
cytes only (Tv excluded). (Bottom panels) Leukocytes were then further gated based on CD19
and CD3 positivity to identity B-cells and T-cells, respectively.
(TIF)
S2 Fig. Viability analysis of leukocytes after Tv co-culture. Total PBMC from live cell gates
(shown in S1 Fig) were analysed for Zombie Red expression to rule out that significant T-cells
or B-cells occurring in live cell gates had compromised membranes.
(TIF)
S3 Fig. Dead trichomonads do not cause death of PBMC. To assure that PBMC death
observed after co-cultures with Tv was specific to live Tv-mediated mechanisms, we co-
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cultured PBMC with dead, intact Tv as a control. We did not observe any decrease in counts of
viable PBMC after co-culture with dead, intact Tv. Data shown are from Tv co-culture with
PBMC at MOI 0.5 for 4 hours and representative of multiple experiments.
(TIF)
S4 Fig. Donor variation in susceptibility to Tv- mediated killing.% death is shown for all
donors used in the study, at MOI 0.5 TvMSA1132 for 4 hours. B-cell versus T-cell susceptibility
was compared using paired (donor-matched), student’s T-test.
(TIF)
S5 Fig.Mycoplasma hominis is undetectable in TvMSA1132 treated with antibiotics and is
the only bacteria present in untreated TvMSA1132 cultures. Chloramphenicol/ tetracycline
treated (TvMSA1132 Cm/Tet) parasites were analyzed for the presence of bacterial symbionts
using universal 16S primers designed to amplify a conserved region of bacterial 16S rDNA.
The designed primers amplify a fragment of 834 bp. (Cm: chloramphenicol; Tet: tetracycline)
specifically in TvMSA1132 untreated parasites. DNA sequencing of the uncloned, amplified
16S bacterial rDNA fragment from untreated TvMSA1132 was analyzed by BLAST analyses of
Genbank. Only one sequence, with 100% homology to 16S region ofM. hominis was detected.
The sequence matched the following accession numbers with 100% identity: (all strains ofM.
hominis) CP009652.1, JN935871.1, NR113679.1, NR041881.1, FP236530.1, AF443616.3,
AF443617.3, AJ002268.1, AJ002267.1, AJ002266.1, and AJ002265.1.
(TIF)
S6 Fig.M. hominis+, but notM. hominis- strains stimulate cytokine release from human
monocyte- derived macrophages. (A) Differentiation of human monocytes to macrophages
(HMDM) was verified by the expression of CD14 and the increase in size. (B)HMDMwere
either unstimulated, treated with LPS, or cultured with heat-inactivated TvG3 for 16 hours.
Supernatants were collected and the indicated cytokines were measured using CBA. Data
shown are average of triplicate wells with standard deviation, and are representative of 3
donors/ independent experiments.
(TIF)
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Summary 
Trichomonas vaginalis is an important human pathogen, especially because most 
infections are asymptomatic1, thus allowing greater spread by asymptomatic carriers. While 
metronidazole, the mainstay treatment, has been in use since the 1960s2, in depth molecular 
understanding of the targets of the drug had remained elusive. The studies in this dissertation, 
identified more Mz protein targets, thus challenging the prevailing hypothesis of limited, 
selective targets3, and also demonstrated some Mz-adducted cysteine residues (Chapter 2). In 
addition, the results presented in Chapter 3 demonstrate that the presence of M. hominis might 
explain some aspect of observed range and severity of symptoms in clinical presentation.  
Insight into metronidazole drug targets 
Previous investigation of metronidazole targets in T. vaginalis using two-dimensional gel 
(2DE) identified seven cytosolic proteins, including thioredoxin reductase3. Investigations into 
other protozoa using similar methodology also identified limited number of proteins4,5.  
T. vaginalis has a large protein-coding genome with significant amplification of gene 
families6. Thus, different isolates of the parasite could have different assortments of orthologs to 
function. In the two strains used in our drug target identification, the only difference was the 
expression of flavin reductase 1 in the sensitive strain7. This likely contributed to the seven 
proteins shared between the adductomes. This stands in contrast to the eight proteins identified in 
the G3 strain by their adducted cysteine residues. Our observations across several proteomics 
studies in the lab have shown that G3 proteomes can vary significantly from other strains. 
Following up this study in various other metronidazole-sensitive and -resistant strains 
would allow the identification of shared targets, especially ones that are conserved in resistant 
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strains. Mechanistically, drug activation potential is limited in resistant strains. For example, in 
B7268-EV parasite which lacks flavin reductase 1, and thus a decreased capacity to reduce and 
eliminate oxygen7, it is conceivable that capacity of functional thioredoxin reductase to activate 
metronidazle3,8 is decreased, as seen with the flavin inhibitor diphenyleneiodonium9. 
Interestingly, the weak driving force for activation of metronidazole preserves resistant strains 
under lower concentration of drug, while sensitive parasites activate more of the drug, leading to 
more extensive adduction and subsequent dysfunction. Thus, identification of shared targets that 
are characterized to be essential for the viability of T. vaginalis could be developed as novel drug 
targets. 
Beyond T. vaginalis, the use of Mz-alkyne can be implemented even in bacterial species 
such as Helicobacter pylori and Clostrium difficile, which were once more susceptible to 
metronidazole. This approach could unlock potential new targets in those organisms as well. 
Insight into immune response to T. vaginalis-M. hominis co-infection 
We observed that monocytes co-cultured with heat-inactivate parasites harboring M. 
hominis elaborated more cytokines than when M. hominis-free parasites are used. Previous works 
suggest that T. vaginalis is sensed through TLR410 and M. hominis is sensed through TLR211. 
Although both TLR2 and TLR4 share common downstream signaling pathways for 
inflammatory cytokine expression12, our observations suggest that TLR2-mediated signaling is 
more significant.  
While we do not observe statistically significant difference in cytotoxic effect secondary 
to M. hominis endosymbiosis, previous study did13. It is likely that the contribution of M. 
hominis to cytotoxicity might depend on the background cytotoxic effect of the axenic T. 
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vaginalis. Moreover, the presence of M. hominis could lead to greater immune recognition of co-
infection, thus leading to symptoms such as leukorrhea, for instance. Epithelial cells are 
important agents in host defense and the different epithelia express different TLRs14. As vaginal 
epithelium does not express TLR414, sensing of the parasite through TLR4 would not be 
expected to happen unless tissue-resident immune cells were encountered. However, the 
presence of M. hominis, which can be sensed by TLR211, a TLR expressed by vaginal 
epithelium14, would result in more robust response, likely leading to more symptoms, which 
might prompt a patient to present to the clinic for treatment. 
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